

CITATION REPORT

List of articles citing

Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators

DOI: 10.1161/01.CIR.94.11.2807
Circulation, 1996, 94, 2807-16.

Source: <https://exaly.com/paper-pdf/86225080/citation-report.pdf>

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
979	Reflections on Recent Clinical Trials in Patients With Heart Failure and Those With Reduced Ventricular Function. 1997 , 2, 147-152		2
978	Recipient Selection and Management Before Cardiac Transplantation. 1997 , 314, 139-152		
977	The AHCPR clinical practice guideline for heart failure revisited. 1997 , 31, 1197-204		7
976	Carvedilol more than an antihypertensive: new data show efficacy in CHF and MI. 1997 , 10, 1-5		
975	Status and prospect of current inotropic agents. 1997 , 7, 1297-1306		6
974	Betabloqueantes en la insuficiencia cardíaca: ¿deben incluirse siempre en la estrategia terapéutica? Argumentos a favor. 1997 , 50, 300-303		
973	Betabloqueantes en la insuficiencia cardíaca: ¿deben incluirse siempre en la estrategia terapéutica? Argumentos en contra. 1997 , 50, 304-307		
972	Carvedilol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders. 1997 , 54, 161-85		71
971	The role of beta-blockers in left ventricular dysfunction and heart failure. 1997 , 54, 501-10		28
970	Digitalis Investigation Group (DIG) trial: a stimulus for further research. <i>American Heart Journal</i> , 1997 , 134, 3-12	4.9	53
969	Impact of carvedilol on mortality and cardiovascular morbidity in patients with chronic heart failure. 1997 , 1, 27-8		
968	Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials. <i>Journal of the American College of Cardiology</i> , 1997 , 30, 27-34	15.1	305
967	Impact of a comprehensive heart failure management program on hospital readmission and functional status of patients with advanced heart failure. <i>Journal of the American College of Cardiology</i> , 1997 , 30, 725-32	15.1	428
966	Clinical trials with implications regarding heart failure therapy. 1997 , 12, 407-417		3
965	Toward the discovery of digitalis derivatives with inotropic selectivity. 1997 , 2, 110-116		13
964	Controlling cardiac arrhythmias: an overview with a historical perspective. 1997 , 80, 4G-15G		19
963	Pharmacotherapy for systolic dysfunction: a review of randomized clinical trials. 1997 , 80, 14H-27H		33

962	Mechanism of action of beta-blocking agents in heart failure. 1997 , 80, 26L-40L		201
961	Effects of beta-adrenergic blockade on survival of patients with chronic heart failure. 1997 , 80, 46L-54L		29
960	Effects of beta blockers on symptoms and functional capacity in heart failure. 1997 , 80, 55L-58L		12
959	Evaluation and treatment strategies in patients at high risk of sudden death post myocardial infarction. 1997 , 20, 753-8		17
958	Dopamine Beta-Hydroxylase Inhibition: A Potential Therapy for the Treatment of Congestive Heart Failure. <i>Heart Failure Reviews</i> , 1998 , 2, 195-201	5	2
957	The role of third-generation beta-blocking agents in chronic heart failure. 1998 , 21, 13-13		79
956	Effect of beta-blocker therapy in patients with coronary artery disease in New York Heart Association classes II and III. The Bezafibrate Infarction Prevention (BIP) Study Group. 1998 , 81, 1455-60		6
955	Beta-adrenergic blockade in chronic heart failure: principles, progress, and practice. 1998 , 41, 39-52		84
954	Comparison of metoprolol and carvedilol pharmacology and cardioprotection in rabbit ischemia and reperfusion model. 1998 , 351, 341-50		42
953	Carvedilol bij hartfalen (2). 1998 , 36, 4-5		
952	Evolving therapeutic concepts and imaging in ischemic cardiomyopathy. 1998 , 5, 598-608		5
951	Successes and failures of current treatment of heart failure. 1998 , 352 Suppl 1, S119-28		71
950	15 years of heart-failure trials: what have we learned?. 1998 , 352 Suppl 1, S129-33		37
949	Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure. <i>Journal of the American College of Cardiology</i> , 1998 , 31, 1336-40	15.1	113
948	Etiology and response to drug treatment in heart failure. <i>Journal of the American College of Cardiology</i> , 1998 , 32, 1167-72	15.1	85
947	Carvedilol. 1998 , 339, 1759-65		208
946	Beta-blocker therapy in young children with congestive heart failure under consideration for heart transplantation. <i>American Heart Journal</i> , 1998 , 136, 19-21	4.9	52
945	Current medical therapy for advanced heart failure. <i>American Heart Journal</i> , 1998 , 135, S231-48	4.9	38

944	Restoring function in failing hearts: the effects of beta blockers. 1998 , 104, 163-9		22
943	A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. 1998 , 339, 1810-6		514
942	Drug administration in patients with diabetes mellitus. Safety considerations. 1998 , 18, 441-55		12
941	Clinical pharmacokinetics of vasodilators. Part II. 1998 , 35, 9-36		56
940	Current treatment recommendations in antiarrhythmic therapy. 1998 , 55, 331-46		15
939	Beta-blockade and amiodarone therapy: twin brothers from different parents. <i>Journal of Cardiac Failure</i> , 1998 , 4, 289-94	3-3	1
938	Beta-receptor blockade decreases carnitine palmitoyl transferase I activity in dogs with heart failure. <i>Journal of Cardiac Failure</i> , 1998 , 4, 121-6	3-3	81
937	Medical therapy of chronic heart failure. Role of ACE inhibitors and beta-blockers. 1998 , 16, 711-25, ix		8
936	Carvedilol treatment of chronic heart failure: a new era. 1998 , 79, S31-4		1
935	Carvedilol use in heart failure. 1998 , 32, 376-81		
934	Pharmacologic Management of Chronic Heart Failure: A Review. 1998 , 2, 168-190		2
933	Treatment of Heart Failure. 1998 , 343-368		
932	A review of why and how we may use beta-blockers in congestive heart failure. 1998 , 113, 800-8		17
931	Innovations in the pharmacologic management of heart failure. 1998 , 9, 172-91; quiz 327-8		6
930	Beta-adrenergic blockade in chronic heart failure. 1998 , 47, 45-55		7
929	Carvedilol prevents severe hypertensive cardiomyopathy and remodeling. 1998 , 16, 871-84		33
928	Current Concepts in the Management of Heart Failure. 1998 , 14, 228-239		
927	Is there a common mechanism of benefit for effective treatment of heart failure?. <i>European Journal of Heart Failure</i> , 1999 , 1, 31-4	12-3	7

926	Advanced Cancer and Comorbid Conditions: Prognosis and Treatment. 1999 , 6, 168-175	0
925	beta-Blockers in congestive heart failure. 1999 , 8, 1795-1805	3
924	Anti-oxidant therapy for the treatment of coronary artery disease. 1999 , 8, 1763-1784	7
923	Major beta blocker mortality trials in chronic heart failure: a critical review. 1999 , 82 Suppl 4, IV14-22	31
922	Carvedilol improves functional class in patients with severe left ventricular dysfunction referred for heart transplantation. 1999 , 13, 426-31	10
921	Sympathetic activation and the role of beta-blockers in chronic heart failure. 1999 , 29, 418-27	16
920	Effects of propranolol treatment on left ventricular function and intracellular calcium regulation in rats with postinfarction heart failure. 1999 , 127, 1671-9	8
919	Sudden death in dilated cardiomyopathy. 1999 , 22, 267-72	18
918	Current issues regarding beta-adrenergic blockade in patients with congestive heart failure: patient selection, nonselective versus selective blockade, management of adverse effects, and indications for withdrawal of therapy. 1999 , 1, 47-54	1
917	Beta-blockers and amiodarone for the primary prevention of sudden cardiac death. 1999 , 1, 274-81	4
916	Cardiac glycosides in the next millennium. 1999 , 41, 247-54	35
915	Beta blocker treatment in heart failure. 1999 , 41, 301-21	34
914	Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure. 1999 , 83, 1201-5	234
913	Beta-adrenergic receptor-G protein-adenylyl cyclase signal transduction in the failing heart. 1999 , 83, 80H-85H	45
912	Prevalence, predictors, and prognosis of reversal of maladaptive remodeling with intensive medical therapy in idiopathic dilated cardiomyopathy. 1999 , 84, 671-6	59
911	Beta-adrenergic blocker mortality trials in congestive heart failure. 1999 , 84, 94R-102R	38
910	Carvedilol blocks the repolarizing K ⁺ currents and the L-type Ca ²⁺ current in rabbit ventricular myocytes. 1999 , 376, 189-201	59
909	Sudden cardiac death. 1999 , 24, 461-538	10

908	Beta-blocker therapy in heart failure: pathophysiology and clinical results. 1999 , 24, 421-60		4
907	Evaluating Health-related quality-of-life outcomes in patients with congestive heart failure. A review of recent randomised controlled trials. 1999 , 15, 19-46		36
906	Increased support for β-blocker use in patients with heart failure. 1999 , 14, 9-11		
905	Beta-blocker treatment of dilated cardiomyopathy with congestive heart failure in children: a multi-institutional experience. 1999 , 18, 269-74		96
904	The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. 1999 , 353, 9-13		3276
903	Tolerability and efficacy of carvedilol in patients with New York Heart Association class IV heart failure. <i>Journal of the American College of Cardiology</i> , 1999 , 33, 924-31	15.1	85
902	Protective effects of carvedilol against doxorubicin-induced cardiomyopathy in rats. 1999 , 65, 1265-74		79
901	Antiadrenergic effect of chronic amiodarone therapy in human heart failure. <i>Journal of the American College of Cardiology</i> , 1999 , 33, 1553-9	15.1	28
900	Clinical profiles of four large pedigrees with familial dilated cardiomyopathy: preliminary recommendations for clinical practice. <i>Journal of the American College of Cardiology</i> , 1999 , 34, 837-47	15.1	47
899	Beta-blockade in heart failure: a comparison of carvedilol with metoprolol. <i>Journal of the American College of Cardiology</i> , 1999 , 34, 1522-8	15.1	140
898	Association of body mass, gender and race with heart failure primarily due to hypertension. <i>Journal of the American College of Cardiology</i> , 1999 , 34, 1602-8	15.1	32
897	Bisoprolol reduced rates of all-cause and cardiovascular mortality among patients with CHF. 1999 , 3, 27-28		
896	HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction—pharmacological approaches. <i>Journal of Cardiac Failure</i> , 1999 , 5, 357-382	3.3	261
895	A review of quality-of-life evaluations in patients with congestive heart failure. 1999 , 16, 247-71		85
894	Metoprolol CR/XL in patients with heart failure: A pilot study examining the tolerability, safety, and effect on left ventricular ejection fraction. <i>American Heart Journal</i> , 1999 , 138, 1158-65	4.9	38
893	Beta-blocker therapy in advanced heart failure: clinical characteristics and long-term outcomes. <i>European Journal of Heart Failure</i> , 1999 , 1, 81-8	12.3	14
892	The carvedilol hibernation reversible ischaemia trial; marker of success (CHRISTMAS). The CHRISTMAS Study Steering Committee and Investigators. <i>European Journal of Heart Failure</i> , 1999 , 1, 191-6	12.3	40
891	Beta blockade in patients with congestive heart failure. Why, who, and how. 2000 , 108, 103-6, 109-10, 116-8		1

890	Improvement in cardiac function and free fatty acid metabolism in a case of dilated cardiomyopathy with CD36 deficiency. 2000 , 64, 731-5	8
889	Risk assessment of left ventricular systolic dysfunction in primary care: cross sectional study evaluating a range of diagnostic tests. 2000 , 320, 220-4	61
888	Update on recent clinical trials in congestive heart failure. 2000 , 15, 293-303	11
887	Steady-state pharmacokinetics of carvedilol and its enantiomers in patients with congestive heart failure. 2000 , 40, 844-53	58
886	Therapy of heart failure. 2000 , 57, 1418-25	30
885	Low dose carvedilol inhibits progression of heart failure in rats with dilated cardiomyopathy. 2000 , 130, 1489-95	72
884	Beta-adrenergic blockers in the treatment of pediatric heart failure. 2000 , 12, 113-118	9
883	Developing clinical practice guidelines for heart failure: creative process and practice implications. 2000 , 20, 379S-384S	2
882	HEART FAILURE SOCIETY OF AMERICA (HFSA) PRACTICE GUIDELINES. 2000 , 20, 495-522	24
881	The effect of beta-blockers on health-related quality of life in patients with heart failure. 2000 , 20, 679-89	21
880	Are all beta blockers the same for heart failure?. 2000 , 6, 153-157	2
879	Role of beta blockers in congestive heart failure. 2000 , 6, 299-312	2
878	Monitoring gas exchange during a constant work rate exercise in patients with left ventricular dysfunction treated with carvedilol. 2000 , 85, 660-4, A10	7
877	Effectiveness of carvedilol alone versus carvedilol + pimobendan for severe congestive heart failure. For the Keio Interhospital Cardiology Study (KICS) Group. 2000 , 85, 1495-7; A7	26
876	Meta-analysis of effect of beta-blocker therapy on mortality in patients with New York Heart Association class IV chronic congestive heart failure. 2000 , 86, 886-9	25
875	Effect of concomitant digoxin and carvedilol therapy on mortality and morbidity in patients with chronic heart failure. 2000 , 86, 1032-5, A10-1	20
874	Effects of carvedilol on heart rate and blood pressure variability in subjects with chronic heart failure. 2000 , 86, 1392-5, A6	28
873	The control of adrenergic function in heart failure: therapeutic intervention. <i>Heart Failure Reviews</i> , 2000 , 5, 101-14	5 30

872	Alterations in adrenergic receptor signaling in heart failure. <i>Heart Failure Reviews</i> , 2000 , 5, 7-16	5	32
871	Predictors of improvement in left ventricular ejection fraction with carvedilol for congestive heart failure. 2000 , 7, 3-7		28
870	The role of cardiac imaging in optimizing therapy in heart failure. 2000 , 7, 81-4		1
869	Effect of heart failure program on cardiovascular drug utilization and dosage in patients with chronic heart failure. 2000 , 23, 909-14		20
868	The effects of neurohormonal antagonism on pathologic left ventricular remodeling in heart failure. 2000 , 2, 90-8		3
867	Deactivation of the sympathetic nervous system in patients with chronic congestive heart failure. 2000 , 2, 225-32		3
866	Sarcoidosis and the Heart. 2000 , 2, 385-398		14
865	Effect of beta 1 blockade with atenolol on progression of heart failure in patients pretreated with high-dose enalapril. <i>European Journal of Heart Failure</i> , 2000 , 2, 407-12	12.3	29
864	The HF epidemic: the need for new treatment strategies. 2000 , 1, S32-4		
863	Perioperative Treatment of Congestive Heart Failure. 2000 , 4, 223-235		
862	Acute cardiovascular effects and pharmacokinetics of carvedilol in healthy dogs. 2000 , 61, 57-60		16
861	Spirolactone for heart failure: spiraling out of control. 2000 , 118, 1522-3		1
860	beta-blockers in heart failure: recently completed and ongoing clinical trials. 2000 , 9, 415-28		1
859	Reversal of heart failure remodeling in women. 2000 , 9, 513-9		1
858	Baseline predictors of tolerability to carvedilol in patients with chronic heart failure. 2000 , 84, 615-9		58
857	Influence of beta-blockers on mortality in chronic heart failure. 2000 , 34, 1440-51		7
856	The inhibitory effects of carvedilol against arrhythmias induced by coronary reperfusion in anesthetized rats. 2000 , 5, 105-12		12
855	Myocardial-directed overexpression of the human beta(1)-adrenergic receptor in transgenic mice. 2000 , 32, 817-30		213

854	beta-blocker improvement in diastolic performance: the yin and yang of ventricular function changes. <i>American Heart Journal</i> , 2000 , 139, 584-6	4.9	6
853	A rationale for the use of beta-blockers as standard treatment for heart failure. <i>American Heart Journal</i> , 2000 , 139, 511-21	4.9	53
852	Predictors of medical events in patients enrolled in the cardiac insufficiency bisoprolol study (CIBIS): A study of the interactions between ß-blocker therapy and occurrence of critical events using analysis of competitive risks. <i>American Heart Journal</i> , 2000 , 139, 262-271	4.9	6
851	Current medical therapy for advanced heart failure. 2000 , 29, 16-32		29
850	The carvedilol hibernation reversible ischaemia trial, marker of success (CHRISTMAS) study. Methodology of a randomised, placebo controlled, multicentre study of carvedilol in hibernation and heart failure. 2000 , 72, 265-74		18
849	Applied physiology: understanding cardiac failure. 2000 , 10, 284-288		
848	Optimising management of patients with advanced heart failure: the importance of preventing progression. 2000 , 16, 87-106		2
847	[Prevention of sudden death in patients awaiting heart transplantation]. 2000 , 53, 736-45		1
846	beta-adrenergic receptor blockade in chronic heart failure. <i>Circulation</i> , 2000 , 101, 558-69	16.7	823
845	Heart failure management using implantable devices for ventricular resynchronization: Comparison of Medical Therapy, Pacing, and Defibrillation in Chronic Heart Failure (COMPANION) trial. COMPANION Steering Committee and COMPANION Clinical Investigators. <i>Journal of Cardiac Failure</i> , 2000 , 6, 276-85	3.3	250
844	[The clinical practice guidelines of the Sociedad Española de Cardiología on cardiomyopathies and myocarditis]. 2000 , 53, 360-93		26
843	Improvement in left ventricular function in response to carvedilol is accompanied by attenuation of neurohumoral activation in patients with dilated cardiomyopathy. <i>Journal of Cardiac Failure</i> , 2000 , 6, 3-10	3.3	45
842	Effects of beta-blockers on neurohormonal activation in patients with congestive heart failure. 2000 , 60, 997-1016		15
841	Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. <i>Journal of the American College of Cardiology</i> , 2000 , 35, 1245-55	15.1	1090
840	Low-dose enoximone improves exercise capacity in chronic heart failure. Enoximone Study Group. <i>Journal of the American College of Cardiology</i> , 2000 , 36, 501-8	15.1	50
839	Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. <i>Journal of the American College of Cardiology</i> , 2000 , 35, 569-82	15.1	1782
838	A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study. <i>Journal of Cardiac Failure</i> , 2001 , 7, 21-9	3.3	341
837	B-type natriuretic peptide levels: a potential novel "white count" for congestive heart failure. <i>Journal of Cardiac Failure</i> , 2001 , 7, 183-93	3.3	127

836	Health-related quality of life measurement in heart failure: challenges for the new millennium. <i>Journal of Cardiac Failure</i> , 2001 , 7, 194-201	3-3	16
835	Dose-related effects of metoprolol on heart rate and pharmacokinetics in heart failure. <i>Journal of Cardiac Failure</i> , 2001 , 7, 311-7	3-3	22
834	Cardiomyopathy and heart failure in diabetes. 2001 , 30, 1031-46		16
833	A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. <i>Journal of the American College of Cardiology</i> , 2001 , 37, 386-91	15.1	552
832	Dilated cardiomyopathy in dialysis patients--beneficial effects of carvedilol: a double-blind, placebo-controlled trial. <i>Journal of the American College of Cardiology</i> , 2001 , 37, 407-11	15.1	113
831	Left ventricular inotropic reserve and right ventricular function predict increase of left ventricular ejection fraction after beta-blocker therapy in nonischemic cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2001 , 37, 818-24	15.1	36
830	Lack of evidence for peripheral alpha(1)- adrenoceptor blockade during long-term treatment of heart failure with carvedilol. <i>Journal of the American College of Cardiology</i> , 2001 , 38, 1463-9	15.1	42
829	Impact of cardiac resynchronization therapy using hemodynamically optimized pacing on left ventricular remodeling in patients with congestive heart failure and ventricular conduction disturbances. <i>Journal of the American College of Cardiology</i> , 2001 , 38, 1957-65	15.1	335
828	Aspirin impairs reverse myocardial remodeling in patients with heart failure treated with beta-blockers. <i>Journal of the American College of Cardiology</i> , 2001 , 38, 1950-6	15.1	26
827	Predicting response to carvedilol for the treatment of heart failure: a multivariate retrospective analysis. <i>Journal of Cardiac Failure</i> , 2001 , 7, 4-12	3-3	22
826	Polypharmacy of heart failure. Creating a rational pharmacotherapeutic protocol. 2001 , 19, 583-96, viii		12
825	Practical aspects of using beta-adrenergic blockade in systolic heart failure. 2001 , 110 Suppl 7A, 68S-73S		8
824	Current role of beta-adrenergic blockers in the management of chronic heart failure. 2001 , 110 Suppl 7A, 81S-94S		102
823	Prognosis determination in heart failure. 2001 , 110 Suppl 7A, 14S-36S		80
822	Pathophysiology of chronic heart failure. 2001 , 110 Suppl 7A, 37S-46S		177
821	Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. <i>American Heart Journal</i> , 2001 , 141, 367-74	4-9	300
820	Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis. <i>American Heart Journal</i> , 2001 , 141, 899-907	4-9	149
819	Regression of left ventricular remodeling in chronic heart failure: Comparative and combined effects of captopril and carvedilol. <i>American Heart Journal</i> , 2001 , 142, 704-13	4-9	42

818	Effect of carvedilol on survival and hemodynamics in patients with atrial fibrillation and left ventricular dysfunction: retrospective analysis of the US Carvedilol Heart Failure Trials Program. <i>American Heart Journal</i> , 2001 , 142, 498-501	4.9	112
817	Congestive heart failure in pediatric patients. <i>American Heart Journal</i> , 2001 , 142, 923-8	4.9	73
816	Carvedilol as therapy in pediatric heart failure: an initial multicenter experience. 2001 , 138, 505-11		146
815	Carvedilol--a new dimension in pediatric heart failure therapy. 2001 , 138, 457-8		7
814	Dose optimization in drug development: role of phase IV trials. 2001 , 1220, 51-65		1
813	Is paradoxical pharmacology a strategy worth pursuing?. 2001 , 22, 273-6		58
812	Beta-blocking in heart failure patients. Balancing the evidence. 2001 , 79, 5-12		2
811	Long-term effect of atenolol on ejection fraction, symptoms, and exercise variables in patients with advanced left ventricular dysfunction. 2001 , 20, 1174-80		12
810	Risk stratification using serum concentrations of cardiac troponin T in patients with end-stage renal disease on chronic maintenance dialysis. 2001 , 312, 69-79		47
809	[Evidence based medical treatment of heart failure]. 2001 , 54, 715-34		6
808	B-type natriuretic peptide in the diagnosis and management of congestive heart failure. 2001 , 19, 557-71		57
807	The looming polypharmacy crisis in the management of patients with heart failure. Potential solutions. 2001 , 19, 541-5		8
806	Observation unit management of heart failure. 2001 , 19, 209-32		36
805	Análisis del uso adecuado de los bloqueadores beta en el postinfarto. 2001 , 54, 1277-1282		4
804	Brain natriuretic peptide-guided therapy for heart failure. 2001 , 33, 422-7		25
803	Torsemide: a pharmacoeconomic review of its use in chronic heart failure. 2001 , 19, 679-703		15
802	Beta-blockade in heart failure: selective versus nonselective agents. 2001 , 1, 3-14		14
801	Carvedilol versus other beta-blockers in heart failure. 2001 , 10, 971-80		5

800	Slowing the progression of CHF. Drug therapy to correct neurohormonal abnormalities. 2001 , 109, 36-8, 41-5		1
799	Influence of carvedilol on the benefits of physical training in patients with moderate chronic heart failure. <i>European Journal of Heart Failure</i> , 2001 , 3, 335-42	12.3	25
798	Optimizing treatment for chronic congestive heart failure in children. 2001 , 29, S237-40		13
797	Managing patients with heart failure. 2001 , 101, 34-40		3
796	Evidence-based treatment of hypertension in patients with type 2 diabetes. 2001 , 56, 96-102		
795	Improved outcomes from a comprehensive management system for heart failure. <i>European Journal of Heart Failure</i> , 2001 , 3, 619-25	12.3	36
794	Beneficial effect of carvedilol on heart rate response to exercise in digitalised patients with heart failure in atrial fibrillation due to idiopathic dilated cardiomyopathy. <i>European Journal of Heart Failure</i> , 2001 , 3, 437-40	12.3	19
793	Changes in the occurrence of mechanical alternans after long-term beta-blocker therapy in patients with chronic heart failure. 2001 , 65, 711-6		12
792	Beta blockers for CHF. Adrenergic blockade dramatically reduces morbidity and mortality. 2001 , 109, 49-56		7
791	Overview of the results of recent beta blocker trials. 2001 , 16, 180-5		19
790	Beta-blockade in hypertension and congestive heart failure. <i>Journal of Cardiovascular Pharmacology</i> , 2001 , 38 Suppl 3, S25-31	3.1	9
789	Low-level inotropic stimulation with type III phosphodiesterase inhibitors in patients with advanced symptomatic chronic heart failure receiving beta-blocking agents. 2001 , 3, 224-31		35
788	Are all beta-blockers the same for chronic heart failure?. 2001 , 3, 124-9		4
787	Translating heart failure guidelines into clinical practice: clinical science and the art of medicine. 2001 , 3, 130-5		8
786	Beta-blocker treatment in heart failure. 2001 , 15, 95-109		26
785	Dobutamine as bridge to angiotensin-converting enzyme inhibitor-nitrate therapy in endstage heart failure. 2001 , 24, 231-6		11
784	Carvedilol in the failing heart. 2001 , 24, 757-66		11
783	What is the optimal medical management of ischemic heart failure?. 2001 , 43, 433-55		19

782	Canine idiopathic dilated cardiomyopathy. Part II: pathophysiology and therapy. 2001 , 162, 182-95	26
781	Diastolic dysfunction in the presence of left ventricular systolic dysfunction: implications of beta-adrenergic blocking therapy. 2001 , 7, 71-76	1
780	Clinic dosing of beta blockers in chronic heart failure. 2001 , 7, 196-200	
779	What is the optimal medical management of ischaemic heart failure?. 2001 , 59, 135-58	5
778	Carvedilol in the treatment of chronic heart failure. 2001 , 2, 831-43	4
777	Economics of chronic heart failure. <i>European Journal of Heart Failure</i> , 2001 , 3, 283-91	12.3 254
776	Clinical trials of antiarrhythmic drugs in postmyocardial infarction and congestive heart failure patients. 2001 , 6, 99-106	2
775	Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. 2001 , 344, 1358-65	235
774	Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. 2002 , 346, 1357-65	402
773	Cardiac-resynchronization therapy for heart failure. 2002 , 346, 1902-5	63
772	New therapeutics for chronic heart failure. 2002 , 53, 59-74	54
771	Sympatholytic therapy in primary hypertension: a user friendly role for the future. 2002 , 16 Suppl 1, S118-23	7
770	Inhibitors of cyclic nucleotide phosphodiesterase PDE3 as adjunct therapy for dilated cardiomyopathy. 2002 , 11, 1529-36	21
769	Role of race in the pharmacotherapy of heart failure. 2002 , 36, 471-8	6
768	Surrogate end points in heart failure. 2002 , 36, 479-88	9
767	Carvedilol reduces the inappropriate increase of ventilation during exercise in heart failure patients. 2002 , 122, 2062-7	69
766	Medical resource use and costs of congestive heart failure after carvedilol use. 2002 , 4, 70-7	4
765	Heart rate modulation by sympathetic nerves in dogs with heart failure. 2002 , 64, 1023-9	18

764	Cardiovascular and renal effects of carvedilol in dogs with heart failure. 2002 , 64, 469-75		21
763	Use of thallium-201 myocardial scintigraphy for the prediction of the response to beta-blocker therapy in patients with dilated cardiomyopathy. <i>Circulation Journal</i> , 2002 , 66, 1139-43	2.9	6
762	The effects of beta-blockers on morbidity and mortality in a population-based cohort of 11,942 elderly patients with heart failure. 2002 , 113, 650-6		110
761	Neurohormonal blockade in chronic heart failure. How much is enough? Can there be too much?. <i>Journal of the American College of Cardiology</i> , 2002 , 39, 79-82	15.1	22
760	Impact of beta-blocker treatment on the prognostic value of currently used risk predictors in congestive heart failure. <i>Journal of the American College of Cardiology</i> , 2002 , 39, 1615-22	15.1	103
759	Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF). <i>Journal of the American College of Cardiology</i> , 2002 , 40, 491-8	15.1	224
758	Myocardial beta-adrenoceptor density one month after acute myocardial infarction predicts left ventricular volumes at six months. <i>Journal of the American College of Cardiology</i> , 2002 , 40, 1216-24	15.1	45
757	Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failure. <i>Journal of Cardiac Failure</i> , 2002 , 8, 416-22	3.3	113
756	Optimising the use of beta-blockers in older patients with heart failure. 2002 , 19, 671-84		4
755	Should beta-blockers be used for the treatment of pediatric patients with chronic heart failure?. 2002 , 4, 771-8		19
754	Effects of angiotensin receptor blockade on haemodynamics and gene expression after myocardial infarction. 2002 , 3, 239-49		4
753	Should reperfusion strategies in myocardial infarction be modified for the very elderly?. <i>American Heart Journal</i> , 2002 , 143, 373-6	4.9	1
752	Carvedilol therapy in pediatric patients with congestive heart failure: a study investigating clinical and pharmacokinetic parameters. <i>American Heart Journal</i> , 2002 , 143, 916-22	4.9	105
751	Beneficial effects of metoprolol on myocardial sympathetic function: Evidence from a randomized, placebo-controlled study in patients with congestive heart failure. <i>American Heart Journal</i> , 2002 , 144, E3	4.9	38
750	The Pediatric Randomized Carvedilol Trial in Children with Heart Failure: rationale and design. <i>American Heart Journal</i> , 2002 , 144, 383-9	4.9	51
749	Intermediate effects of treatment with metoprolol or carvedilol in children with left ventricular systolic dysfunction. 2002 , 21, 906-9		39
748	BNP in hormone-guided treatment of heart failure. 2002 , 13, 151-5		36
747	Use of ejection fraction (or lack thereof), morbidity/mortality and heart failure drug trials: a review. 2002 , 84, 119-32		11

746	Prevention of cardiovascular diseases. Coronary artery disease, congestive heart failure, and stroke. 2002 , 18, 463-83, vii		9
745	Beta-blockers: new standard therapy for heart failure. 2002 , 77, 839-45; quiz 845-6		15
744	Beta-blockers in chronic heart failure: considerations for selecting an agent. 2002 , 77, 1199-206		17
743	Correspondence. 2002 , 63, 497-497		
742	Structural, functional, and molecular characterization of the SHHF model of heart failure. 2002 , 283, H1775-84		76
741	Effects of long-term beta-blocker (metoprolol or carvedilol) therapy on QT variability in subjects with chronic heart failure secondary to ischemic cardiomyopathy. 2002 , 90, 1113-7		44
740	Carvedilol: a nonselective beta blocking agent with antioxidant properties. 2002 , 8, 173-7, 190		30
739	Beta-adrenergic blockade 2002: a pharmacologic odyssey in chronic heart failure. 2002 , 8, 262-9; 283		3
738	Contemporary use of beta receptor antagonists in chronic heart failure. 2002 , 28, 207-13		
737	Use of metoprolol in dogs with acquired cardiac disease. 2002 , 4, 23-8		10
736	Atenolol improves ventricular function without changing plasma noradrenaline but decreasing plasma atrial natriuretic factor in chronic heart failure. 2002 , 22, 261-8		4
735	Effects of carvedilol on heart rate dynamics in patients with congestive heart failure. 2002 , 7, 133-8		18
734	Energy metabolism in the normal and failing heart: potential for therapeutic interventions. <i>Heart Failure Reviews</i> , 2002 , 7, 115-30	5	182
733	Outpatient management of heart failure. <i>Heart Failure Reviews</i> , 2003 , 8, 345-8	5	3
732	Beta-adrenergic Receptor Blockers in Heart Failure. 2003 , 5, 475-485		1
731	Use of 123I-MIBG scintigraphy to assess the impact of carvedilol on cardiac adrenergic neuronal function in childhood dilated cardiomyopathy. 2003 , 30, 1651-6		6
730	Long-term effects of beta blocker therapy on P-wave duration and dispersion in congestive heart failure patients: a new effect?. 2003 , 36, 111-6		18
729	Vasodilating beta-adrenoceptor blockers as cardiovascular therapeutics. 2003 , 100, 215-34		75

728	Expanding role of beta-blockade in the management of chronic heart failure. 2003 , 23, 451-9	3
727	Hemodynamic response to intensive unloading therapy (furosemide and nitroprusside) in patients >70 years of age with left ventricular systolic dysfunction and decompensated chronic heart failure. 2003 , 92, 1050-6	20
726	Prevention and management of chronic heart failure in management of asymptomatic patients. 2003 , 91, 4F-9F	120
725	Pharmacologic therapy for patients with chronic heart failure and reduced systolic function: review of trials and practical considerations. 2003 , 91, 18F-40F	85
724	QT dispersion after beta-blocker therapy (carvedilol or metoprolol) in children with heart failure. 2003 , 91, 1497-500, A8	5
723	Prevalence, predictors, and prognostic implications of improvement in left ventricular systolic function and clinical status in patients >70 years of age with recently diagnosed systolic heart failure. 2003 , 92, 166-72	27
722	Effects of cold exposure on submaximal exercise performance and adrenergic activation in patients with congestive heart failure and the effects of beta-adrenergic blockade (carvedilol or metoprolol). 2003 , 92, 548-53	16
721	Beta-blocker treatment of chronic heart failure: comparison of carvedilol and metoprolol. 2003 , 9, 263-70	6
720	The most important issue: use beta blockers. 2003 , 9, 251-4	
719	Switching between beta blockers in heart failure patients: rationale and practical considerations. 2003 , 9, 271-8	11
718	Measurement of carvedilol in plasma by high-performance liquid chromatography with electrochemical detection. 2003 , 798, 187-91	38
717	Chronic treatment with carvedilol improves ventricular function and reduces myocyte apoptosis in an animal model of heart failure. 2003 , 3, 6	20
716	Sympathetic nervous system activity and ventricular tachyarrhythmias: recent advances. 2003 , 8, 75-89	33
715	The renin-angiotensin system and the long-term complications of diabetes: pathophysiological and therapeutic considerations. 2003 , 20, 607-21	60
714	The use of beta-blockers in the treatment of chronic heart failure. 2003 , 15, 439-46	
713	Beta-blockers for heart failure: why, which, when, and where. 2003 , 87, 339-71	20
712	Heart failure. 2003 , 348, 2007-18	1497
711	Selective versus nonselective beta-blockade for heart failure therapy: are there lessons to be learned from the COMET trial?. <i>Journal of Cardiac Failure</i> , 2003 , 9, 444-53	3-3 59

710	The points for pacing. <i>Journal of the American College of Cardiology</i> , 2003 , 42, 1460-2	15.1	5
709	Carvedilol: a review of its use in chronic heart failure. 2003 , 63, 1697-741		45
708	Tolerability to beta-blocker therapy among heart failure patients in clinical practice. <i>Journal of Cardiac Failure</i> , 2003 , 9, 203-9	3.3	34
707	The effect of digoxin on the quality of life in patients with heart failure. <i>Journal of Cardiac Failure</i> , 2003 , 9, 4-12	3.3	41
706	PDE3 inhibition in dilated cardiomyopathy: reasons to reconsider. <i>Journal of Cardiac Failure</i> , 2003 , 9, 475-80	3.3	27
705	Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial. 2003 , 362, 14-21		258
704	Beta-blockers for chronic heart failure: surviving longer but feeling better?. 2003 , 92, 1-8		14
703	Marked improvement in left ventricular ejection fraction during long-term beta-blockade in patients with chronic heart failure: clinical correlates and prognostic significance. <i>American Heart Journal</i> , 2003 , 145, 292-9	4.9	94
702	The effect of beta-adrenergic blockers on the prognostic value of peak exercise oxygen uptake in patients with heart failure. 2003 , 22, 70-7		43
701	Disruption of type 5 adenylyl cyclase gene preserves cardiac function against pressure overload. 2003 , 100, 9986-90		166
700	Treatment of chronic heart failure with beta adrenergic blockade beyond controlled clinical trials: the BRING-UP experience. 2003 , 89, 299-305		67
699	Importance of beta blockade in the treatment of advanced heart failure. 2003 , 89, 1442-4		10
698	Extended-release metoprolol succinate in chronic heart failure. 2003 , 37, 701-10		14
697	Selection of endpoints for heart failure clinical trials. <i>European Journal of Heart Failure</i> , 2003 , 5, 717-23	12.3	33
696	Beta-blocker benefit according to severity of heart failure. <i>European Journal of Heart Failure</i> , 2003 , 5, 281-9	12.3	19
695	A Review of Cardiovascular Disease and Treatment Differences in Women. 2003 , 16, 157-163		1
694	Myocardial beta-1 adrenoceptor down-regulation in aging and heart failure: implications for beta-blocker use in older adults with heart failure. <i>European Journal of Heart Failure</i> , 2003 , 5, 709-15	12.3	35
693	Titration of beta-blockers in heart failure. How to maximize benefit while minimizing adverse events. 2003 , 113, 63-70; quiz 3		7

692	Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. 2003 , 289, 712-8	197
691	Beta-adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failure. 2003 , 13, 379-82	121
690	Risk of mortality and heart failure exacerbations associated with inhaled beta-adrenoceptor agonists among patients with known left ventricular systolic dysfunction. 2003 , 123, 1964-9	97
689	A new method using pulmonary gas-exchange kinetics to evaluate efficacy of beta-blocking agents in patients with dilated cardiomyopathy. 2003 , 124, 954-61	8
688	Facts and principles learned at the 31st Annual Williamsburg Conference on Heart Disease. 2004 , 17, 106-15	
687	Impact of appropriate pharmaceutical therapy for chronic conditions on direct medical costs and workplace productivity: a review of the literature. 2004 , 7, 61-75	18
686	Beta-adrenergic blockers in heart failure: review of mechanisms of action and clinical outcomes. 2004 , 9, 243-55	33
685	Beta-blocker induced bradycardia-should we pace?. <i>European Journal of Heart Failure</i> , 2004 , 6, 449-51	12.3 3
684	Effects of carvedilol on left ventricular remodelling in chronic stable heart failure: a cardiovascular magnetic resonance study. 2004 , 90, 760-4	60
683	Heart failure in a district general hospital: are target doses of beta-blockers realistic?. 2004 , 97, 133-9	23
682	Management of chronic heart failure in the community: role of a hospital based open access heart failure service. 2004 , 90, 755-9	16
681	Pharmacodynamics of beta-blockers in heart failure: lessons from the carvedilol or metoprolol European trial. 2004 , 9, 117-28	10
680	Metoprolol CR/XL improves systolic and diastolic left ventricular function in patients with chronic heart failure. 2004 , 21, 215-23	11
679	B-type natriuretic peptide: the level and the drug--partners in the diagnosis of congestive heart failure. 2004 , 10, 3-27	48
678	Effect of bisoprolol on right ventricular function and brain natriuretic peptide in patients with heart failure. 2004 , 10, 127-32	22
677	Heart failure management in the emergency department observation unit. 2004 , 46, 465-85	13
676	Cardiovascular drug class specificity: beta-blockers. 2004 , 47, 11-33	114
675	Relation between contractile reserve and improvement in left ventricular function with beta-blocker therapy in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. 2004 , 93, 854-9	51

674	Cardiac remodeling in coronary artery disease. 2004 , 93, 17B-20B		40
673	Commentary on the Carvedilol or Metoprolol European Trial (COMET). 2004 , 93, 40B-2B		113
672	Landmark studies: the Australia/New Zealand Heart Failure Collaborative Group (ANZ) Trial and the US Carvedilol Trials Program. 2004 , 93, 30B-4B		7
671	Practical guidelines to optimize effectiveness of beta-blockade in patients postinfarction and in those with chronic heart failure. 2004 , 93, 69B-73B		4
670	Relation of dose of carvedilol to reduction in QT dispersion in patients with mild to moderate heart failure secondary to ischemic or to idiopathic dilated cardiomyopathy. 2004 , 94, 1459-62		8
669	Effects of bisoprolol in patients with stable congestive heart failure. 2004 , 53, 167-70		12
668	[Prediction of intolerance to beta blocker therapy in chronic heart failure patients using BNP]. 2004 , 53, 298-304		2
667	Biologic rationale for the use of beta-blockers in the treatment of heart failure. <i>Heart Failure Reviews</i> , 2004 , 9, 91-7	5	42
666	Beta-blockers in heart failure: are pharmacological differences clinically important?. <i>Heart Failure Reviews</i> , 2004 , 9, 123-30	5	40
665	Pharmacokinetics and pharmacodynamics of beta blockers in heart failure. <i>Heart Failure Reviews</i> , 2004 , 9, 131-7	5	25
664	A novel data mining approach to the identification of effective drugs or combinations for targeted endpoints--application to chronic heart failure as a new form of evidence-based medicine. 2004 , 18, 483-9		29
663	Is too much neurohormonal blockade harmful?. 2004 , 6, 169-75		4
662	Pharmacologic effects on cardiac remodeling. 2004 , 1, 9-13		5
661	How should COMET influence heart failure practice?. 2004 , 1, 67-71		2
660	Beta-blockers in heart failure: is more better?. 2004 , 1, 77-81		
659	Comprehensive adrenergic receptor blockade with carvedilol is superior to beta-1-selective blockade with metoprolol in patients with heart failure: COMET. 2004 , 1, 82-8		1
658	Restoration of heart rate turbulence by titrated beta-blocker therapy in patients with advanced congestive heart failure: positive correlation with enhanced vagal modulation of heart rate. 2004 , 15, 752-6		28
657	Myocardial systolic synchrony measured by Doppler tissue imaging as a role of predictor of left ventricular ejection fraction improvement in severe congestive heart failure. 2004 , 17, 1245-50		4

656	Factores pronósticos en la insuficiencia cardíaca. 2004 , 30, 437-443		
655	Efectos del carvedilol en la capacidad funcional, función ventricular izquierda, catecolaminas y estrés oxidativo en pacientes con insuficiencia cardíaca crónica. 2004 , 57, 1053-1058		5
654	Effects of Carvedilol on Functional Capacity, Left Ventricular Function, Catecholamines, and Oxidative Stress in Patients With Chronic Heart Failure. 2004 , 57, 1053-1058		
653	Selection of patients for heart transplantation in the current era of heart failure therapy. <i>Journal of the American College of Cardiology</i> , 2004 , 43, 787-93	15.1	75
652	Therapeutic update: non-selective beta- and alpha-adrenergic blockade in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. <i>Journal of the American College of Cardiology</i> , 2004 , 44, 497-502	15.1	43
651	Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure. <i>Journal of the American College of Cardiology</i> , 2004 , 44, 1825-30	15.1	80
650	Remote titration of carvedilol for heart failure patients by advanced practice nurses. <i>Journal of Cardiac Failure</i> , 2004 , 10, 219-24	3.3	28
649	Chronic left ventricular failure in the community: Prevalence, prognosis, and predictors of the complete clinical recovery with return of cardiac size and function to normal in patients undergoing optimal therapy. <i>Journal of Cardiac Failure</i> , 2004 , 10, 250-7	3.3	22
648	Rationale, design, and methods for a pivotal randomized clinical trial for the assessment of a cardiac support device in patients with New York health association class III-IV heart failure. <i>Journal of Cardiac Failure</i> , 2004 , 10, 185-92	3.3	45
647	Impact of 6 months of therapy with carvedilol on muscle sympathetic nerve activity in heart failure patients. <i>Journal of Cardiac Failure</i> , 2004 , 10, 496-502	3.3	46
646	Worldwide clinical experience with the CorCap Cardiac Support Device. <i>Journal of Cardiac Failure</i> , 2004 , 10, S225-33	3.3	38
645	Beta-adrenergic receptor blockade and the angiotensin-converting enzyme deletion polymorphism in patients with chronic heart failure. <i>European Journal of Heart Failure</i> , 2004 , 6, 17-21	12.3	24
644	Beta-blockade in the management of systolic dysfunction. 2004 , 34, 1157-70		6
643	International Society for Heart and Lung Transplantation: Practice guidelines for management of heart failure in children. 2004 , 23, 1313-33		179
642	Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. <i>American Heart Journal</i> , 2004 , 147, 324-30	4.9	135
641	Association between chronic heart failure and inhaled beta-2-adrenoceptor agonists. <i>American Heart Journal</i> , 2004 , 148, 915-20	4.9	49
640	Effect of drug therapy for heart failure on quality of life. 2004 , 6, 256-61		3
639	Do evidence-based treatments provide incremental benefits to patients with congestive heart failure already receiving angiotensin-converting enzyme inhibitors? A secondary analysis of one-year outcomes from the Assessment of Treatment with Lisinopril and Survival (ATLAS) study. 2004 , 26, 691-703		17

638	Metoprolol and coronary artery bypass grafting surgery: does intraoperative metoprolol attenuate acute beta-adrenergic receptor desensitization during cardiac surgery?. 2004 , 98, 1224-31, table of contents	5
637	The quality of life in heart failure: just talking about it will not make it better. <i>European Journal of Heart Failure</i> , 2004 , 6, 535-7	12.3 2
636	Ventricular dysrhythmias in heart failure. 2004 , 19, S11-26	2
635	[Clinical trials of beta-blockers in heart failure: history, overview and future prospects]. 2004 , 59, 517-26	1
634	Alternative therapies for orthotopic heart transplantation. 2005 , 330, 88-101	3
633	Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure. 2005 , 15, 137-42	93
632	Late gadolinium cardiovascular magnetic resonance in the assessment of myocardial viability. 2005 , 16, 365-72	12
631	Comparison of low and high doses of carvedilol on restoration of cardiac function and calcium-handling proteins in rat failing heart. 2005 , 32, 553-60	13
630	Relationship of the implantable cardioverter defibrillator and chronic resynchronization therapy: the perfect marriage?. 2005 , 10, 24-33	1
629	Effect of beta-blocker therapy on mortality rates and future myocardial infarction rates in patients with coronary artery disease but no history of myocardial infarction or congestive heart failure. 2005 , 95, 827-31	19
628	Drugs for left ventricular remodeling in heart failure. 2005 , 96, 10L-18L	105
627	The COMET trial. 2005 , 11, 39-47	3
626	BNP-guided therapy not better than expert's clinical assessment for beta-blocker titration in patients with heart failure. 2005 , 11, 248-53; quiz 254-5	37
625	The effect of coenzyme Q10 on idiopathic chronic dilated cardiomyopathy in children. 2005 , 26, 361-6	11
624	When to initiate beta-blockers in heart failure: is it ever too early?. 2005 , 2, 94-9	3
623	Heart failure following anterior myocardial infarction: an indication for ventricular restoration, a surgical method to reverse post-infarction remodeling. <i>Heart Failure Reviews</i> , 2004 , 9, 241-54	5 7
622	Impact of a standardized titration protocol with carvedilol in heart failure: safety, tolerability, and efficacy-a report from the GESICA registry. 2005 , 19, 125-34	13
621	[Evidence-based medicine with hawthorn extract]. 2005 , 34, 58-64	

620	Effects of carvedilol on oxidative stress and chronotropic response to exercise in patients with chronic heart failure. <i>European Journal of Heart Failure</i> , 2005 , 7, 1033-9	12.3	29
619	The effects of long-term beta-blockade on the ventilatory responses to exercise in chronic heart failure. <i>European Journal of Heart Failure</i> , 2005 , 7, 612-7	12.3	31
618	Patient perception of the effect of treatment with candesartan in heart failure. Results of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. <i>European Journal of Heart Failure</i> , 2005 , 7, 650-6	12.3	20
617	Effect of a community heart failure clinic on uptake of beta blockers by patients with obstructive airways disease and heart failure. 2006 , 92, 331-6		25
616	Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies. 2005 , 26, 1461-74		644
615	Severe Heart Failure in the ICU. 2005 , 212-238		1
614	Carvedilol in chronic heart failure: past, present and future. 2005 , 1, 723-34		3
613	Effects of nebivolol on left ventricular function in elderly patients with chronic heart failure: results of the ENECA study. <i>European Journal of Heart Failure</i> , 2005 , 7, 631-9	12.3	47
612	Titration of carvedilol in elderly heart failure patients. 2005 , 14, 230-5		6
611	Early outcomes of a care coordination-enhanced telehome care program for elderly veterans with chronic heart failure. 2005 , 11, 20-7		63
610	Valsartan in chronic heart failure. 2005 , 39, 460-9		6
609	Role of echocardiography in the contemporary management of chronic heart failure. 2005 , 3, 51-70		4
608	Six minute corridor walk test as an outcome measure for the assessment of treatment in randomized, blinded intervention trials of chronic heart failure: a systematic review. 2005 , 26, 778-93		203
607	Effect of beta-blockers on cardiac function and calcium handling protein in postinfarction heart failure rats. 2005 , 128, 1812-21		47
606	Increased gene expression of collagen Types I and III is inhibited by beta-receptor blockade in patients with dilated cardiomyopathy. 2005 , 26, 2698-705		13
605	Dissociation between improvement in left ventricular performance and functional class in patients with chronic heart failure. <i>Journal of Cardiovascular Pharmacology</i> , 2005 , 46, 262-8	3.1	7
604	Tratamiento de la insuficiencia cardíaca en fase muy avanzada. 2005 , 12, 315-324		
603	Idiopathic dilated cardiomyopathy in children: a single medical center's experience. 2005 , 68, 368-72		9

602	Using the emergency department clinical decision unit for acute decompensated heart failure. 2005 , 23, 569-88, viii		22
601	Chronic heart failure: an overview of conventional treatment versus novel approaches. 2005 , 2, 628-38		30
600	Myocardial substrate metabolism in the normal and failing heart. 2005 , 85, 1093-129		1354
599	Carvedilol effectively blocks oxidative stress-mediated downregulation of sarcoplasmic reticulum Ca ²⁺ -ATPase 2 gene transcription through modification of Sp1 binding. 2005 , 328, 116-24		50
598	Should stable UNOS Status 2 patients be transplanted?. 2005 , 24, 178-83		33
597	Predictors of response to cardiac resynchronization therapy (PROSPECT)--study design. <i>American Heart Journal</i> , 2005 , 149, 600-5	4.9	165
596	Practical considerations of beta-blockade in the management of the post-myocardial infarction patient. <i>American Heart Journal</i> , 2005 , 149, 984-93	4.9	18
595	[Congestive heart failure in Spain: cost-effectiveness and cost-benefit analyses of treatment with beta-blockers]. 2005 , 205, 149-56		3
594	[Expert Consensus document on beta-adrenergic receptor blockers]. 2005 , 58, 65-90		14
593	Effects of beta-blocker therapy on ventilatory responses to exercise in patients with heart failure. <i>Journal of Cardiac Failure</i> , 2005 , 11, 333-9	3.3	42
592	Beta-blockers, exercise, and ventilation in chronic heart failure. <i>Journal of Cardiac Failure</i> , 2005 , 11, 340-3	3.3	5
591	Canine nonischemic left ventricular dysfunction: a model of chronic human cardiomyopathy. <i>Journal of Cardiac Failure</i> , 2005 , 11, 638-44	3.3	26
590	Does carvedilol impair insulin sensitivity in heart failure patients without diabetes?. <i>Journal of Cardiac Failure</i> , 2005 , 11, 590-4	3.3	14
589	A novel tool to assess systolic asynchrony and identify responders of cardiac resynchronization therapy by tissue synchronization imaging. <i>Journal of the American College of Cardiology</i> , 2005 , 45, 677-84	15.1	322
588	ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). <i>Journal of the American College of Cardiology</i> , 2005 , 46, e1-82	15.1	1119
587	Are there clinically important differences between beta-blockers in heart failure?. 2005 , 1, 57-66		1
586	Alterations in cAMP-mediated signaling and their role in the pathophysiology of dilated cardiomyopathy. 2005 , 68, 25-48		50
585	Heart failure in the adult patient with congenital heart disease. <i>Journal of Cardiac Failure</i> , 2005 , 11, 306-3	3.3	20

584	Beta blockade in diabetic heart failure. 2006 , 2, 89-99		1
583	The effect of carvedilol on mortality risk in heart failure patients with diabetes: results of a meta-analysis. 2006 , 22, 287-96		59
582	Modification of myocardial substrate use as a therapy for heart failure. 2006 , 3, 490-8		68
581	Pharmacodynamics of Carvedilol in Conscious, Healthy Dogs. 2006 , 20, 297-304		11
580	Novel imaging strategies for predicting remodeling and evolution of heart failure: targeting the Renin-Angiotensin system. 2006 , 2, 231-47		5
579	The timing for transplantation superior genetics or social prejudice?. <i>Journal of the American College of Cardiology</i> , 2006 , 47, 2243-4	15.1	2
578	Beta-blocker use and outcomes among hospitalized heart failure patients. <i>Journal of the American College of Cardiology</i> , 2006 , 47, 2462-9	15.1	82
577	Rationale and design of a randomized controlled trial to assess the safety and efficacy of cardiac resynchronization therapy in patients with asymptomatic left ventricular dysfunction with previous symptoms or mild heart failure--the RESynchronization reVERses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study. <i>American Heart Journal</i> , 2006 , 151, 288-94	4.9	68
576	Multifaceted intervention to promote beta-blocker use in heart failure. <i>American Heart Journal</i> , 2006 , 151, 992-8	4.9	19
575	Rapid titration of carvedilol in patients with congestive heart failure: a randomized trial of automated telemedicine versus frequent outpatient clinic visits. <i>American Heart Journal</i> , 2006 , 151, 844-51	4.9	32
574	Clinical predictors of marked improvement in left ventricular performance after cardiac resynchronization therapy in patients with chronic heart failure. <i>American Heart Journal</i> , 2006 , 151, 477-81	4.9	35
573	Beta blockade in the post-myocardial infarction setting: pharmacologic rationale and clinical evidence. 2006 , 9, 96-101		1
572	The effect of beta-adrenergic receptor antagonism in cardiac sympathetic neuronal remodeling in patients with heart failure. 2006 , 106, 29-34		25
571	The long-term survival benefit conferred by intermittent dobutamine infusions and oral amiodarone is greater in patients with idiopathic dilated cardiomyopathy than with ischemic heart disease. 2006 , 108, 244-50		9
570	Competitive displacement of phosphoinositide 3-kinase from beta-adrenergic receptor kinase-1 improves postinfarction adverse myocardial remodeling. 2006 , 291, H1754-60		25
569	Upregulated neurohumoral factors are associated with left ventricular remodeling and poor prognosis in rats with monocrotaline-induced pulmonary arterial hypertension. <i>Circulation Journal</i> , 2006 , 70, 1208-15	2.9	38
568	Long-term prognosis of dilated cardiomyopathy revisited: an improvement in survival over the past 20 years. <i>Circulation Journal</i> , 2006 , 70, 376-83	2.9	41
567	CHARITY: Chagas cardiomyopathy bisoprolol intervention study: a randomized double-blind placebo force-titration controlled study with Bisoprolol in patients with chronic heart failure secondary to Chagas cardiomyopathy [NCT00323973]. 2006 , 7, 21		15

566	Role of β Adrenoceptor Desensitization in Heart Failure. 2006 , 17, 384-394	2
565	Carvedilol: molecular and cellular basis for its multifaceted therapeutic potential. 2001 , 19, 152-71	92
564	Carvedilol case history: the discovery and development of the first β blocker for the treatment of congestive heart failure. 2006 , 1, 85-9	6
563	Magnetic resonance imaging in the evaluation of non-ischemic cardiomyopathies: current applications and future perspectives. <i>Heart Failure Reviews</i> , 2006 , 11, 313-23	5 31
562	[Drug treatment of chronic heart failure]. 2006 , 95 Suppl 4, 36-54; quiz 55-6	19
561	Prospective single-arm protocol of carvedilol in children with ventricular dysfunction. 2006 , 27, 336-42	39
560	Exercise testing with concurrent beta-blocker usage: is it useful? What do we learn?. 2006 , 3, 81-8	6
559	Dobutamine stress echocardiography: does it predict response to beta-blockers in patients with heart failure?. 2006 , 3, 96-102	3
558	Beta-blocker therapy for heart failure: should the therapeutic target be dose or heart rate reduction?. 2006 , 12, 206-10; quiz 211-2	10
557	Randomized, double-blind comparison of acute beta1-blockade with 50 mg metoprolol tartrate vs 25 mg carvedilol in normal subjects. 2006 , 12, 254-7	6
556	COMPARE: comparison of the effects of carvedilol CR and carvedilol IR on left ventricular ejection fraction in patients with heart failure. 2006 , 98, 53L-59L	9
555	Prevençi3 de la diabetes mellitus en los pacientes con insuficiencia cardiaca. 2006 , 6, 50C-57C	
554	Optimal medical therapy for heart failure. 2006 , 48, 372-85	15
553	Comparison of the epidemiology and co-morbidities of heart failure in the pediatric and adult populations: a retrospective, cross-sectional study. 2006 , 6, 23	37
552	The investigation and treatment of chronic heart failure. 2006 , 34, 215-219	
551	Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. 2006 , 27, 562-8	84
550	Selecting patients for cardiac resynchronization therapy: electrical or mechanical dyssynchrony?. 2006 , 27, 1270-81	138
549	Differential change in left ventricular mass and regional wall thickness after cardiac resynchronization therapy for heart failure. 2006 , 27, 1423-30	51

548	Drug trials in pediatric heart failure: hype or improved clinical science?. 2006 , 2, 281-6		1
547	Effect of beta-blocker therapy on functional status in patients with heart failure--a meta-analysis. <i>European Journal of Heart Failure</i> , 2006 , 8, 522-31	12.3	35
546	Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure. <i>European Journal of Heart Failure</i> , 2006 , 8, 355-60	12.3	147
545	Patients' knowledge and beta blocker treatment improve prognosis of patients from a heart failure clinic. <i>European Journal of Heart Failure</i> , 2006 , 8, 187-90	12.3	17
544	Profile of carvedilol controlled-release: a new once-daily formulation of carvedilol. 2006 , 7, 2533-46		12
543	The effect of neurohormonal antagonists in reducing heart failure hospitalizations. 2006 , 22, 139-50		4
542	Understanding chronic heart failure. 2007 , 92, 812-6		8
541	Levosimendan and prostaglandin E1 for uptitration of beta-blockade in patients with refractory, advanced chronic heart failure. <i>European Journal of Heart Failure</i> , 2007 , 9, 202-8	12.3	32
540	Beta-blockade at low doses restoring the physiological balance in myocytic antagonism. 2007 , 32, 225-30		6
539	Exercise Testing of Patients with Left Ventricular Dysfunction. 2007 , 211-237		
538	Potential of metabolic agents as adjunct therapies in heart failure. 2007 , 3, 525-35		5
537	Carvedilol prevents and reverses hypertrophy-induced cardiac dysfunction. 2007 , 80, 166-76		12
536	Cardiac resynchronization therapy: clinical results and evolution of candidate selection. 2007 , 9, 194-1106		7
535	Reversal of heart failure remodeling with age. 2002 , 11, 299-304		8
534	Surgical therapy for heart failure. 2007 , 5, 251-63		3
533	Paediatric heart failure trials...and tribulations. 2007 , 17, 354-5		2
532	Improvement of cardiac function persists long term with medical therapy for left ventricular systolic dysfunction. 2007 , 12, 220-6		
531	Arg389Gly-beta1-adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol. 2007 , 17, 941-9		70

530	Safety and efficacy of carvedilol in very elderly diabetic patients with heart failure. 2007 , 8, 675-82		8
529	The early anti-oxidant effect of carvedilol predicts the clinical course in congestive heart failure patients. 2007 , 8, 453-6		10
528	Heart Failure and Its Management With β -Blockade: Potential Applications of Once-Daily Therapy. 2007 , 9, 28-35		13
527	Keys to successful cardiac resynchronization therapy. <i>American Heart Journal</i> , 2007 , 153, 18-24	4.9	8
526	Beta-blocker dosing in community-based treatment of heart failure. <i>American Heart Journal</i> , 2007 , 153, 1029-36	4.9	41
525	Relation of early improvement in coronary flow reserve to late recovery of left ventricular function after beta-blocker therapy in patients with idiopathic dilated cardiomyopathy. <i>American Heart Journal</i> , 2007 , 153, 1080.e1-6	4.9	12
524	Tolerability and dose-related effects of nebivolol in elderly patients with heart failure: data from the Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS) trial. <i>American Heart Journal</i> , 2007 , 154, 109-15	4.9	61
523	Randomized active-controlled study comparing effects of treatment with carvedilol versus metoprolol in patients with left ventricular dysfunction after acute myocardial infarction. <i>American Heart Journal</i> , 2007 , 154, 116-22	4.9	13
522	Carvedilol can restore the multifractal properties of heart beat dynamics in patients with advanced congestive heart failure. 2007 , 132, 76-80		19
521	Carvedilol: use in chronic heart failure. 2007 , 5, 21-31		23
520	Suboptimal medical therapy in patients with systolic heart failure is associated with less improvement by cardiac resynchronization therapy. 2007 , 115, 214-9		19
519	Treatment of chronic heart failure with carvedilol in daily practice: the SATELLITE survey experience. 2007 , 122, 149-55		38
518	Predictors of therapeutic response to beta-blockers in patients with heart failure in Taiwan. 2007 , 106, 641-8		9
517	beta-Adrenoceptor antagonists in elderly patients with heart failure: a critical review of their efficacy and tolerability. 2007 , 24, 1031-44		12
516	Cardiac hypertrophy: mechanisms and therapeutic opportunities. 2007 , 9, 623-52		82
515	Quality of life assessment in heart failure interventions: a 10-year (1996-2005) review. 2007 , 14, 589-607		29
514	Beta-blocker therapy induces ventricular resynchronization in dilated cardiomyopathy with narrow QRS complex. <i>Journal of the American College of Cardiology</i> , 2007 , 49, 778-83	15.1	35
513	Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-treated black population with heart failure: results from A-HeFT. <i>Journal of Cardiac Failure</i> , 2007 , 13, 331-9	3.3	60

512	Quality of life and prognosis in heart failure: results of the Beta-Blocker Evaluation of Survival Trial (BEST). <i>Journal of Cardiac Failure</i> , 2007 , 13, 732-7	3.3	36
511	Chronic Heart Failure. 2007 ,		
510	Electrophysiological effects of carvedilol on rabbit heart pacemaker cells. 2007 , 48, 347-58		12
509	Prescription of beta-blockers in patients with advanced heart failure and preserved left ventricular ejection fraction. Clinical implications and survival. <i>European Journal of Heart Failure</i> , 2007 , 9, 962-963	12.3	1
508	The effect of beta-blocker therapy on quality of life in heart failure patients: a systematic review and meta-analysis. 2007 , 16, 152-9		37
507	Association of beta-blocker dose with serum procollagen concentrations and cardiac response to spironolactone in patients with heart failure. 2007 , 27, 801-12		5
506	Blunted hemodynamic response and reduced oxygen delivery with exercise in anemic heart failure patients with systolic dysfunction. 2007 , 13, 71-7		2
505	Getting to the heart of asthma: can "beta blockers" be useful to treat asthma?. 2007 , 115, 360-74		31
504	Beta-adrenergic receptor blockade and pediatric dilated cardiomyopathy. 2007 , 24, 51-57		6
503	Evidence-based treatment of chronic heart failure. 2007 , 33, 2-17		1
502	To add amiodarone or not: that is the question. 2008 , 15, 7-9		
501	Carvedilol versus controlled-release metoprolol for elderly veterans with heart failure. 2008 , 56, 1021-7		11
500	Improving medication compliance in patients with heart failure. 2008 , 101, 274-7		5
499	Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers. 2008 , 101, 865-9		158
498	Dosing of beta-blocker therapy before, during, and after hospitalization for heart failure (from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure). 2008 , 102, 1524-9		60
497	Comparison of late mortality in hospitalized patients >70 years of age with systolic heart failure receiving beta blockers versus those not receiving beta blockers. 2008 , 102, 1711-7		4
496	Comparison of pharmacodynamics between carvedilol and metoprolol in rats with isoproterenol-induced cardiac hypertrophy: effects of carvedilol enantiomers. 2008 , 589, 194-200		12
495	Baseline characteristics of patients randomized in The Resynchronization Reverses Remodeling In Systolic Left Ventricular Dysfunction (REVERSE) study. 2008 , 14, 66-74		23

494	Controlled-release carvedilol. 2008 , 8, 271-82		3
493	Beta-blocker therapy in heart failure in the elderly. 2008 , 125, 149-53		8
492	The safety and effects of the beta-blocker, nadolol, in mild asthma: an open-label pilot study. 2008 , 21, 134-41		102
491	Effects of carvedilol on left ventricular function and oxidative stress in infants and children with idiopathic dilated cardiomyopathy: a 12-month, two-center, open-label study. 2008 , 30, 702-14		32
490	Two decades of cardiac transplantation at the Montreal Heart Institute. 2008 , 24, 217-21		3
489	Dilated cardiomyopathy and left bundle branch block associated with ingestion of colloidal gold and silver is reversed by British antiLewisite and vitamin E: the potential toxicity of metals used as health supplements. 2008 , 24, 397-9		7
488	Comprehensive adrenergic blockade post myocardial infarction left ventricular dysfunction. 2008 , 26, 79-89, vii		1
487	Traditional and novel approaches to management of heart failure: successes and failures. 2008 , 26, 59-72, vi		15
486	Surgical restoration of the postinfarction dilated ventricle. 2008 , 4, 361-70		2
485	Pediatric heart failure therapy with beta-adrenoceptor antagonists. 2008 , 10, 125-34		12
484	Norepinephrine- and epinephrine-induced distinct beta2-adrenoceptor signaling is dictated by GRK2 phosphorylation in cardiomyocytes. 2008 , 283, 1799-807		53
483	Prognostic value of sequential measurements of amino-terminal prohormone of B-type natriuretic peptide in ambulatory heart failure patients. <i>European Journal of Heart Failure</i> , 2008 , 10, 404-11	12.3	16
482	Beneficial effects of bisoprolol on the survival of hypertensive diastolic heart failure model rats. <i>European Journal of Heart Failure</i> , 2008 , 10, 446-53	12.3	36
481	Role of beta adrenergic receptor polymorphisms in heart failure: systematic review and meta-analysis. <i>European Journal of Heart Failure</i> , 2008 , 10, 3-13	12.3	66
480	Impact of cardioselective beta-blockers on mortality in patients with chronic obstructive pulmonary disease and atherosclerosis. 2008 , 178, 695-700		94
479	Treatment of heart failure beyond practice guidelines. Role of cardiac remodeling. <i>Circulation Journal</i> , 2008 , 72 Suppl A, A1-7	2.9	9
478	Predictive factors of recurrent angina after acute coronary syndrome: the global registry acute coronary events from China (Sino-GRACE). 2008 , 121, 12-16		10
477	Carvedilol in the treatment of elderly patients with chronic heart failure. 2008 , 3, 55-70		1

476	Severe Heart Failure. 2008 , 559-587		
475	Low drug doses may improve outcomes in chronic disease. 2009 , 191, 511-3		15
474	omega-3 polyunsaturated fatty acid supplementation for the treatment of heart failure: mechanisms and clinical potential. 2009 , 84, 33-41		79
473	The current role of beta-blockers in chronic heart failure: with special emphasis on the CIBIS III trial. 2009 , 11, A15-A20		1
472	Myocardial beta-adrenergic receptor density assessed by 11C-CGP12177 PET predicts improvement of cardiac function after carvedilol treatment in patients with idiopathic dilated cardiomyopathy. 2009 , 50, 220-5		46
471	Is there a role for carvedilol in the management of pediatric heart failure? A meta analysis and e-mail survey of expert opinion. 2009 , 2, 74-8		2
470	Long-term left ventricular reverse remodelling with cardiac resynchronization therapy: results from the CARE-HF trial. <i>European Journal of Heart Failure</i> , 2009 , 11, 480-8	12.3	143
469	Self-assessment of health status is associated with inflammatory activation and predicts long-term outcomes in chronic heart failure. <i>European Journal of Heart Failure</i> , 2009 , 11, 163-9	12.3	44
468	Levosimendan vs. dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVE. <i>European Journal of Heart Failure</i> , 2009 , 11, 304-11	12.3	115
467	Beta-receptor selectivity of carvedilol and metoprolol succinate in patients with heart failure (SELECT trial): a randomized dose-ranging trial. 2009 , 29, 883-90		12
466	Metabolism of protocatechuic acid influences fatty acid oxidation in rat heart: new anti-angina mechanism implication. 2009 , 77, 1096-104		28
465	Pharmacologic management of patients with both heart failure and diabetes. 2009 , 6, 126-32		3
464	Modulation of left ventricular dilation remodeling with epicardial restraint devices in postmyocardial infarction heart failure. 2009 , 6, 229-35		4
463	Gln(27)-->Glu beta(2)-adrenergic receptor polymorphism in heart failure patients: differential clinical and oxidative response to carvedilol. 2009 , 104, 374-8		19
462	B-type natriuretic peptide predicts benefit from a home-based nurse care in chronic heart failure. <i>Journal of Cardiac Failure</i> , 2009 , 15, 233-40	3.3	6
461	Beta-blocker tolerability in elderly heart failure patients. 2009 , 136, 93-4; author reply 94-5		4
460	Extent of left ventricular scar predicts outcomes in ischemic cardiomyopathy patients with significantly reduced systolic function: a delayed hyperenhancement cardiac magnetic resonance study. 2009 , 2, 34-44		162
459	Heart Failure, Iodine Intake and Thyroid Hormones. 2009 , 1073-1086		

458	2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. <i>Journal of the American College of Cardiology</i> , 2009 , 52, 152-176	15.1	1224
457	Resting heart rate does not reflect the degree of beta-blockade in subjects with heart failure on chronic beta-blocker therapy. 2009 , 27, 42-8		5
456	Beta-blocker use for the stages of heart failure. 2009 , 84, 718-29		55
455	Dose-dependent prognostic effect of carvedilol in patients with chronic heart failure--special reference to transcardiac [corrected] gradient of norepinephrine. <i>Circulation Journal</i> , 2009 , 73, 2270-5	2.9	18
454	Global gene expression profiling in the failing myocardium. <i>Circulation Journal</i> , 2009 , 73, 1568-76	2.9	73
453	Mechanisms of remodelling: a question of life (stem cell production) and death (myocyte apoptosis). <i>Circulation Journal</i> , 2009 , 73, 1973-82	2.9	36
452	Rapid carvedilol up-titration in hospitalized patients with left ventricular systolic dysfunction--data from the Carvedilol in Hospital: Up-titration Limits after Acute Patients Admission registry. 2010 , 11, 352-8		3
451	Comparative effects of carvedilol vs bisoprolol for severe congestive heart failure. <i>Circulation Journal</i> , 2010 , 74, 1127-34	2.9	32
450	Role of beta-blocker therapy in pediatric heart failure. 2010 , 4, 45-58		12
449	Coadministration of carvedilol attenuates nitrate tolerance by preventing cytochrome p450 depletion. <i>Circulation Journal</i> , 2010 , 74, 1711-7	2.9	9
448	Population pharmacokinetics of R- and S-carvedilol in Japanese patients with chronic heart failure. 2010 , 33, 1378-84		19
447	A histamine H1-receptor blocker ameliorates development of heart failure in dogs independently of beta-adrenergic receptor blockade. 2010 , 105, 787-94		31
446	High-dose carvedilol therapy for mechanical circulatory assisted patients. 2010 , 13, 88-91		14
445	Effect of the cholinesterase inhibitor donepezil on cardiac remodeling and autonomic balance in rats with heart failure. 2010 , 60, 67-74		52
444	Role of beta-adrenergic receptor gene polymorphisms in the long-term effects of beta-blockade with carvedilol in patients with chronic heart failure. 2010 , 24, 49-60		54
443	Novel therapeutic option for refractory heart failure in elderly patients with chronic kidney disease by incremental peritoneal dialysis. 2010 , 55, 49-54		42
442	Long-term beta-blocker therapy improves diastolic function even without the therapeutic effect on systolic function in patients with reduced ejection fraction. 2010 , 56, 176-82		16
441	Heart failure: epidemiology, investigation and management. 2010 , 38, 473-478		1

440	Neurohormonal Blocking Agents in the Treatment of Patients with Left Ventricular Dysfunction and Heart Failure. 2010 , 83-116		
439	βAdrenoceptors in cardiovascular and respiratory diseases. 287-320		
438	Comparing the Effects of Carvedilol Enantiomers on Regression of Established Cardiac Hypertrophy Induced by Pressure Overload. 2010 , 26, 75		3
437	Poor tolerance of beta-blockers by elderly patients with heart failure. 2010 , 5, 365-8		5
436	Chronic Cardiac Failure. 2010 , 257-268		
435	Clinical trials update from the American Heart Association meeting 2009: HEAAL, FAIR-HF, J-CHF, HeartMate II, PACE and a meta-analysis of dose-ranging studies of beta-blockers in heart failure. <i>European Journal of Heart Failure</i> , 2010 , 12, 197-201	12.3	12
434	Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients. 2010 , CD007613		36
433	Cell therapy for heart failure: the need for a new therapeutic strategy. 2010 , 8, 1107-26		12
432	N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study. <i>Journal of the American College of Cardiology</i> , 2010 , 55, 645-53	15.1	178
431	Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach. <i>Journal of the American College of Cardiology</i> , 2010 , 56, 392-406	15.1	272
430	Measurement of inverse agonism in βAdrenoceptors. 2010 , 485, 37-60		5
429	[Betablockers in heart failure. If they are so good, why aren't they being used?]. 2010 , 134, 156-7		
428	beta-Adrenoceptor inverse agonists in asthma. 2010 , 10, 254-9		36
427	Effects of beta-blockers on ventilation efficiency in heart failure. <i>American Heart Journal</i> , 2010 , 159, 1067-73	4.9	34
426	beta-Blocker use following myocardial infarction: low prevalence of evidence-based dosing. <i>American Heart Journal</i> , 2010 , 160, 435-442.e1	4.9	38
425	Is target dose of beta-blocker more important than achieved heart rate or heart rate change in patients with systolic chronic heart failure?. 2010 , 28, 93-100		13
424	Chronic heart failure: contemporary diagnosis and management. 2010 , 85, 180-95		139
423	Patient assessment for cardiac resynchronization therapy: Past, present and future of imaging techniques. 2010 , 26, 27-34		10

422	Outpatient management of pediatric heart failure. 2010 , 6, 515-29, ix	7
421	Clinical and demographic predictors of outcomes in recent onset dilated cardiomyopathy: results of the IMAC (Intervention in Myocarditis and Acute Cardiomyopathy)-2 study. <i>Journal of the American College of Cardiology</i> , 2011 , 58, 1112-8	15.1 152
420	Phase II trials in heart failure: the role of cardiovascular imaging. <i>American Heart Journal</i> , 2011 , 162, 3-15, ix	6
419	Improvement of left ventricular diastolic function induced by β blockade: a comparison between nebivolol and metoprolol. 2011 , 51, 168-76	18
418	Effect on mode of death of heart failure treatment started with bisoprolol followed by Enalapril, compared to the opposite order: results of the randomized CIBIS III trial. 2011 , 29, 89-98	14
417	Medical therapy for chronic heart failure. 2011 , 378, 713-21	64
416	Myocardial Dysfunction, Ventricular Assist Devices, and Extracorporeal Life Support. 2011 , 319-337	
415	Antagonism of the Sympathetic Nervous System in Heart Failure. 2011 , 674-693	3
414	Management of cardiac and pulmonary treatment-related side effects. 2011 , 67-94	2
413	Beneficial association of β blocker therapy on recovery from severe acute heart failure treatment: data from the Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support trial. 2011 , 39, 940-4	34
412	Telephone titration of heart failure medications. 2011 , 26, 29-36	8
411	Cardiomyopathy and heart failure in children: anesthetic implications. 2011 , 21, 577-84	13
410	New perspectives for the treatment of pulmonary hypertension. 2011 , 163, 125-40	47
409	Effect of left ventricular reverse remodeling on long-term prognosis after therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and β blockers in patients with idiopathic dilated cardiomyopathy. 2011 , 107, 1065-70	50
408	Population-based analysis of class effect of β blockers in heart failure. 2011 , 107, 1196-202	15
407	Polymorphisms of the beta adrenergic receptor predict left ventricular remodeling following acute myocardial infarction. 2011 , 25, 251-8	16
406	Randomized clinical trials and the treatment of pediatric cardiomyopathy. 2011 , 31, 7-11	2
405	Determination of trace carvedilol by solid substrate-room temperature phosphorimetry, based on its activating effect on hypochlorite-oxidizing amaranth using sodium dodecyl benzene sulphonate as sensitizer. 2011 , 26, 734-40	3

404	β-blockers and their mortality benefits: underprescribed in heart failure and chronic obstructive pulmonary disease. 2011 , 7, 43-53		2
403	Influence of order and type of drug (bisoprolol vs. enalapril) on outcome and adverse events in patients with chronic heart failure: a post hoc analysis of the CIBIS-III trial. <i>European Journal of Heart Failure</i> , 2011 , 13, 765-72	12.3	23
402	Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial. <i>European Journal of Heart Failure</i> , 2011 , 13, 670-80	12.3	124
401	cGMP signals modulate cAMP levels in a compartment-specific manner to regulate catecholamine-dependent signaling in cardiac myocytes. 2011 , 108, 929-39		120
400	Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. 2011 , 32, 2507-15		207
399	Central sleep apnea. 2011 , 98, 411-9		6
398	Beta-blockers and cardiovascular outcomes in dialysis patients: a cohort study in Ontario, Canada. 2012 , 27, 1591-8		16
397	Drug and device therapy for patients with chronic heart failure. 2012 , 10, 313-5		
396	Heart rate achieved or beta-blocker dose in patients with chronic heart failure: which is the better target?. <i>European Journal of Heart Failure</i> , 2012 , 14, 737-47	12.3	62
395	Impact of peripheral arterial disease on functional limitation in congestive heart failure: results from the national health and nutrition examination survey (1999-2004). 2012 , 2012, 306852		8
394	Primary prevention with a defibrillator: are therapies always really optimized before implantation?. 2012 , 14, 1572-7		
393	Nurse-led titration of angiotensin converting enzyme inhibitors, beta-adrenergic blocking agents and angiotensin receptor blockers for patients with left ventricular systolic dysfunction. 2012 ,		
392	Safety and tolerability of once-daily controlled-release carvedilol 10-80 mg in Japanese patients with chronic heart failure. <i>Circulation Journal</i> , 2012 , 76, 668-74	2.9	5
391	Contemporary medical management of systolic heart failure. <i>Circulation Journal</i> , 2012 , 76, 268-77	2.9	20
390	Cardiac Failure. 2012 , 1021-1031		
389	Myocardial reverse remodeling. 2012 , 30, 172-81		69
388	Effects of beta-blockade on exercise performance at high altitude: a randomized, placebo-controlled trial comparing the efficacy of nebivolol versus carvedilol in healthy subjects. 2012 , 30, 240-8		24
387	A plea for the wider use of CRT-P in candidates for cardiac resynchronisation therapy. <i>Heart Failure Reviews</i> , 2012 , 17, 767-75	5	8

386	How to improve outcomes: should we put more emphasis on programming and medical care and less on patient selection?. <i>Heart Failure Reviews</i> , 2012 , 17, 791-802	5	1
385	Eblockers in stage B: a precursor of heart failure. 2012 , 8, 237-45		1
384	Pharmacist intervention in primary care to improve outcomes in patients with left ventricular systolic dysfunction. 2012 , 33, 314-24		72
383	Factors associated with improvement in ejection fraction in clinical practice among patients with heart failure: findings from IMPROVE HF. <i>American Heart Journal</i> , 2012 , 163, 49-56.e2	4.9	86
382	Improvement in ejection fraction--but do not forget the basics, the medications. <i>American Heart Journal</i> , 2012 , 163, e27; author reply e29	4.9	
381	New insights into mechanisms of action of carvedilol treatment in chronic heart failure patients--a matter of time for contractility. <i>Journal of Cardiac Failure</i> , 2012 , 18, 183-93	3.3	19
380	The pharmacogenetics of β adrenergic receptor antagonists in the treatment of hypertension and heart failure. 2012 , 8, 767-90		13
379	Relationship of beta-blocker dose with outcomes in ambulatory heart failure patients with systolic dysfunction: results from the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) trial. <i>Journal of the American College of Cardiology</i> , 2012 , 60, 208-15	15.1	70
378	Role of delayed contrast enhancement cardiovascular magnetic resonance at 3.0 Tesla in patients with chronic heart failure. 2012 , 64, 197-201		
377	Assessment of ventricular remodeling in heart failure clinical trials. 2012 , 9, 328-36		16
376	What will be the role of I-123 MIBG in improving the outcome of medically treated heart failure patients?. 2012 , 19, 1198-205; quiz 1206-10		2
375	A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application?. 2012 , 33, 165-75		60
374	Medication dosing in outpatients with heart failure after implementation of a practice-based performance improvement intervention: findings from IMPROVE HF. 2012 , 18, 9-17		55
373	Reverse chamber remodelling following adrenergic-induced advanced cardiac dilatation and pump dysfunction. 2012 , 107, 238		10
372	Systematic review of genuine versus spurious side-effects of beta-blockers in heart failure using placebo control: recommendations for patient information. 2013 , 168, 3572-9		78
371	β Blockers for the prevention of sudden cardiac death in heart failure patients: a meta-analysis of randomized controlled trials. 2013 , 13, 52		64
370	Effect of race on left ventricular ejection fraction decline after initial improvement with beta blockers in patients with non-ischemic cardiomyopathy: a retrospective analysis. 2013 , 13, 183-90		1
369	Clinical features, and in-hospital and 1-year mortalities of patients with acute heart failure and severe renal dysfunction. Data from the Italian Registry IN-HF Outcome. 2013 , 168, 3691-7		19

368	Fulminant myocarditis. 2013 , 29, 465-83		67
367	Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). <i>European Journal of Heart Failure</i> , 2013 , 15, 110-8	12.3	210
366	Improvement of guideline βblocker prescribing in heart failure: a cluster-randomized pragmatic trial of a pharmacy intervention. <i>Journal of Cardiac Failure</i> , 2013 , 19, 525-32	3.3	4
365	Medical management is the way to go for ventricular reconstruction post STICH?. 2013 , 55, 476-80		
364	Beyond medication prescription as performance measures: optimal secondary prevention medication dosing after acute myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2013 , 62, 1791-801	15.1	87
363	Beta blocker treatment of heart failure patients with ongoing cocaine use. 2013 , 168, 2919-20		9
362	Comparison of left ventricular reverse remodeling induced by cardiac contractility modulation and cardiac resynchronization therapy in heart failure patients with different QRS durations. 2013 , 167, 889-93		13
361	Benefits of βblockers in patients with heart failure and reduced ejection fraction: network meta-analysis. 2013 , 346, f55		183
360	Minimal dose for effective clinical outcome and predictive factors for responsiveness to carvedilol: Japanese chronic heart failure (J-CHF) study. 2013 , 164, 238-44		24
359	Switching from carvedilol to bisoprolol ameliorates adverse effects in heart failure patients with dizziness or hypotension. 2013 , 61, 417-22		4
358	Cost-effectiveness of heart failure therapies. 2013 , 10, 338-54		48
357	βBlocker therapy and cardiovascular outcomes in patients who have undergone percutaneous coronary intervention after ST-elevation myocardial infarction. 2013 , 28, 139-47		18
356	Beneficial effects of beta-blockers on left ventricular function and cellular energy reserve in patients with heart failure. 2013 , 27, 455-64		21
355	Natural history of left ventricular ejection fraction in patients with heart failure. 2013 , 6, 680-6		41
354	Pharmacologic Management of Heart Failure in the Ambulatory Setting. 2013 , 241-269		1
353	Effects of βadrenergic blockade on left ventricular remodeling among Hispanics and African Americans with chronic heart failure. 2013 , 36, 595-602		6
352	Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation. <i>European Journal of Heart Failure</i> , 2013 , 15, 324-33	12.3	29
351	Association between adrenergic receptor genotypes and beta-blocker dose in heart failure patients: analysis from the HF-ACTION DNA substudy. <i>European Journal of Heart Failure</i> , 2013 , 15, 258-66	12.3	34

350	The need for multicentre cardiovascular clinical trials in Asia. 2013 , 10, 355-62		3
349	Impact of beta2-agonists, beta-blockers, and their combination on cardiac function in elderly male patients with chronic obstructive pulmonary disease. 2013 , 8, 1157-65		11
348	Heart Failure. 2013 , 540-556		
347	2014 Korean guidelines for appropriate utilization of cardiovascular magnetic resonance imaging: a joint report of the Korean Society of Cardiology and the Korean Society of Radiology. 2014 , 15, 659-88		22
346	2014 korean guidelines for appropriate utilization of cardiovascular magnetic resonance imaging: a joint report of the korean society of cardiology and the korean society of radiology. <i>Korean Circulation Journal</i> , 2014 , 44, 359-85	2.2	12
345	Different effects of prolonged βadrenergic stimulation on heart and cerebral artery. 2014 , 3, 204-210		16
344	The PREDICT (increasing the participation of the elderly in clinical trials) study: the charter and beyond. 2014 , 7, 457-68		32
343	Heart rate: a prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rate-lowering properties. <i>European Journal of Heart Failure</i> , 2014 , 16, 76-85	12.3	56
342	Pyridostigmine prevents peripheral vascular endothelial dysfunction in rats with myocardial infarction. 2014 , 41, 202-9		8
341	Response to Sexton: Inhibiting the renin-angiotensin-aldosterone system in patients with heart failure and renal dysfunction: common sense or nonsense?. 2014 , 7, 537-40		3
340	The baroreceptor as a therapeutic target for heart failure. 2014 , 7, 301-9		8
339	Medical therapy in adults with congenital heart disease. 2014 , 10, 167-78		14
338	Beta-blockers and ivabradine in chronic heart failure: from clinical trials to clinical practice. 2014 , 14, 101-10		11
337	βadrenoceptor blockers valuable but higher doses not necessary. 2014 , 78, 1076-9		9
336	Heart failure in children: etiology and treatment. 2014 , 165, 228-33		53
335	Polypharmacy in heart failure: drugs to use and avoid. 2014 , 10, 577-90		8
334	Comparable benefit of βblocker therapy in heart failure across regions of the world: meta-analysis of randomized clinical trials. 2014 , 30, 898-903		12
333	Right ventricular reverse remodeling, but not subjective clinical amelioration, predicts long-term outcome after surgery for isolated severe tricuspid regurgitation. <i>Circulation Journal</i> , 2014 , 78, 385-92	2.9	13

332	Evaluation of synergistic effects of resynchronization therapy and a β -blocker up-titration strategy based on a predefined patient-management program: the RESTORE study. 2015 , 38, 2-7		6
331	Relationship between beta-blocker and angiotensin-converting enzyme inhibitor dose and clinical outcome following acute myocardial infarction. <i>Circulation Journal</i> , 2015 , 79, 632-40	2.9	16
330	Nurse-led titration of angiotensin converting enzyme inhibitors, beta-adrenergic blocking agents, and angiotensin receptor blockers for people with heart failure with reduced ejection fraction. 2015 , CD009889		24
329	Reverse Remodeling in Systolic Heart Failure. 2015 , 23, 173-81		14
328	Hormone replacement therapy in heart failure. 2015 , 30, 277-84		28
327	Reverse Remodeling Achieved by Combination Therapy With High-Dose Beta Blocker and Cardiac Resynchronization. 2015 , 56, 462-5		3
326	Impact of β -blocker selectivity on long-term outcomes in congestive heart failure patients with chronic obstructive pulmonary disease. 2015 , 10, 515-23		32
325	Reverse Cardiac Remodeling: A Marker of Better Prognosis in Heart Failure. 2015 , 104, 502-6		20
324	Ionic liquid phase microextraction combined with fluorescence spectrometry for preconcentration and quantitation of carvedilol in pharmaceutical preparations and biological media. 2015 , 23, 30		5
323	Non- β -blocking R-carvedilol enantiomer suppresses Ca^{2+} waves and stress-induced ventricular tachyarrhythmia without lowering heart rate or blood pressure. 2015 , 470, 233-42		24
322	Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction: safety and efficacy in patients with and without cardiac resynchronization therapy. <i>European Journal of Heart Failure</i> , 2015 , 17, 1066-74	12.3	62
321	Third-generation beta-adrenoceptor antagonists in the treatment of hypertension and heart failure. 2015 , 117, 5-14		22
320	Cardiac Adrenergic Nervous System and Left Ventricular Remodeling. 2015 , 350, 321-6		6
319	The effect of reverse remodeling on long-term survival in mildly symptomatic patients with heart failure receiving cardiac resynchronization therapy: results of the REVERSE study. 2015 , 12, 524-530		66
318	Developing evidence-based treatments for the management of pediatric heart failure. 2015 , 39, 53-55		
317	Improvement in left ventricular ejection fraction and reverse remodeling in elderly heart failure patients on intense NT-proBNP-guided therapy. 2015 , 191, 286-93		8
316	Dual Angiotensin Receptor and Neprilysin Inhibition with Sacubitril/Valsartan in Chronic Systolic Heart Failure: Understanding the New PARADIGM. 2015 , 49, 1237-51		13
315	Nurse-coordinated collaborative disease management improves the quality of guideline-recommended heart failure therapy, patient-reported outcomes, and left ventricular remodelling. <i>European Journal of Heart Failure</i> , 2015 , 17, 442-52	12.3	53

314	Heart failure management in skilled nursing facilities: a scientific statement from the American Heart Association and the Heart Failure Society of America. <i>Journal of Cardiac Failure</i> , 2015 , 21, 263-99	3.3	27
313	Does the target dose of neurohormonal blockade matter for outcome in Systolic heart failure in octogenarians?. 2015 , 187, 666-72		13
312	Effect of Chronic Heart Rate Reduction by I(f) Current Inhibitor Ivabradine on Left Ventricular Remodeling and Systolic Performance in Middle-Aged Rats With Postmyocardial Infarction Heart Failure. 2015 , 20, 299-312		6
311	Nemaline myopathy and heart failure: role of ivabradine; a case report. 2015 , 15, 5		13
310	Treatment of hypertension in patients with coronary artery disease: A scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. 2015 , 9, 453-98		39
309	Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction. 2015 , 3, 487-496		139
308	Medical Treatment of Heart Failure and Coronary Heart Disease. 2015 , 533-560		
307	Effect of anti-heart failure therapy on diastolic function in children with single-ventricle circulations. 2015 , 25, 1293-9		11
306	Treatment of Hypertension in Patients With Coronary Artery Disease: A Scientific Statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 1998-2038	15.1	97
305	Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. <i>Circulation</i> , 2015 , 131, e435-70	16.7	80
304	Data Mining as a Powerful Tool for Creating Novel Drugs in Cardiovascular Medicine: The Importance of a "Back-and-Forth Loop" Between Clinical Data and Basic Research. 2015 , 29, 309-15		3
303	The safety and tolerability of beta blockers in heart failure with reduced ejection fraction: is the current underutilization of this evidence-based therapy justified?. 2015 , 14, 1855-63		8
302	ESC guidelines adherence is associated with improved survival in patients from the Norwegian Heart Failure Registry. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015 , 1, 31-6	6.4	19
301	Therapeutic approaches of uncomplicated arterial hypertension in patients with COPD. 2015 , 35, 1-7		5
300	Hazards of perioperative β blockers are likely to be dose related. 2015 , 115, 944		1
299	High Dose β Blocker Therapy Triggers Additional Reverse Remodeling in Patients With Idiopathic Non-Ischemic Cardiomyopathy. 2016 , 57, 717-724		11
298	Vidarabine, an Anti-Herpes Virus Agent, Protects Against the Development of Heart Failure With Relatively Mild Side-Effects on Cardiac Function in a Canine Model of Pacing-Induced Dilated Cardiomyopathy. <i>Circulation Journal</i> , 2016 , 80, 2496-2505	2.9	5
297	Beneficial Effect on Surrogate Markers of Heart Failure with Bisoprolol Up-Titration to Recommended Targets in Korean Patients with Heart Failure and Left Ventricular Systolic Dysfunction. 2016 , 34, 172-9		2

296	Relationships among achieved heart rate, β -blocker dose and long-term outcomes in patients with heart failure with atrial fibrillation. 2016 , 3, e000520		6
295	The role of pharmacotherapy in the prevention of sudden cardiac death in patients with heart failure. <i>Heart Failure Reviews</i> , 2016 , 21, 415-31	5	4
294	Prognostic impact of preexisting hypertension and high systolic blood pressure at admission in patients hospitalized for systolic heart failure. 2016 , 67, 418-23		8
293	Pharmacologic and Endovascular Reversal of Left Ventricular Remodeling. <i>Journal of Cardiac Failure</i> , 2016 , 22, 829-39	3.3	11
292	A meta-analysis of the effects of β -adrenergic blockers in chronic heart failure. 2016 , 12, 2489-2496		8
291	Prognosis of heart failure with preserved ejection fraction treated with β -blockers: A propensity matched study in the community. 2016 , 222, 594-602		10
290	Treatment with Optimal Dose Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Has a Positive Effect on Long-Term Survival in Older Individuals (Aged >70 Years) and Octogenarians with Systolic Heart Failure. 2016 , 33, 675-83		6
289	Sympathetic Nerve Activity Efferent Drive and Beta-Blocker Treatment - Effect of Interaction in Systolic Heart Failure. <i>Circulation Journal</i> , 2016 , 80, 2149-54	2.9	6
288	Advantages, disadvantages and alternatives to using adult heart failure clinical trials to guide pediatric heart failure therapy. 2016 , 43, 7-9		3
287	Effects of β -blockers on left ventricular remodeling in patients with preserved ejection fraction after acute myocardial infarction. 2016 , 221, 765-9		8
286	Tolvaptan Improves the Long-Term Prognosis in Patients With Congestive Heart Failure With Preserved Ejection Fraction as Well as in Those With Reduced Ejection Fraction. 2016 , 57, 600-6		17
285	Rationale and design of the Children's Oncology Group (COG) study ALTE1621: a randomized, placebo-controlled trial to determine if low-dose carvedilol can prevent anthracycline-related left ventricular remodeling in childhood cancer survivors at high risk for developing heart failure. 2016 , 14, 187		18
284	A Review of the External Validity of Clinical Trials with Beta-Blockers in Heart Failure. 2016 , 10, 163-171		3
283	Hypertension and coronary artery disease: epidemiology, physiology, effects of treatment, and recommendations : A joint scientific statement from the Austrian Society of Cardiology and the Austrian Society of Hypertension. 2016 , 128, 467-79		16
282	A Review of New Pharmacologic Treatments for Patients With Chronic Heart Failure With Reduced Ejection Fraction. 2016 , 56, 936-47		3
281	Prognostic value of left ventricular reverse remodeling and performance improvement after cardiac resynchronization therapy: A prospective study. 2016 , 204, 6-11		20
280	Role of Ivabradine in the Treatment of Patients With Cardiovascular Disease. 2016 , 50, 475-85		6
279	New-onset left bundle branch block-associated idiopathic nonischemic cardiomyopathy and left ventricular ejection fraction response to guideline-directed therapies: The NEOLITH study. 2016 , 13, 933-42		24

278	Heart Rate or Beta-Blocker Dose? Association With Outcomes in Ambulatory Heart Failure Patients With Systolic Dysfunction: Results From the HF-ACTION Trial. 2016 , 4, 109-115		44
277	Time course of left ventricular reverse remodeling in response to pharmacotherapy: clinical implication for heart failure prognosis in patients with idiopathic dilated cardiomyopathy. 2016 , 31, 545-54		24
276	Thirty Years of Evidence on the Efficacy of Drug Treatments for Chronic Heart Failure With Reduced Ejection Fraction: A Network Meta-Analysis. 2017 , 10,		109
275	Heart Failure. 2017 , 93-141		
274	Variation in hospital performance for heart failure management in the National Heart Failure Audit for England and Wales. 2017 , 103, 55-62		11
273	Inhibition of the Sympathetic Nervous System. 2017 , 97-124		
272	The control of cardiac ventricular excitability by autonomic pathways. 2017 , 174, 97-111		13
271	Prognostic role of β -blocker selectivity and dosage regimens in heart failure patients. Insights from the MECKI score database. <i>European Journal of Heart Failure</i> , 2017 , 19, 904-914	12.3	19
270	Effect of beta-adrenergic blockade with carvedilol on cachexia in severe chronic heart failure: results from the COPERNICUS trial. 2017 , 8, 549-556		47
269	Activation of PPAR- β in the early stage of heart failure maintained myocardial function and energetics in pressure-overload heart failure. 2017 , 312, H305-H313		45
268	Achieving a Maximally Tolerated β -Blocker Dose in Heart Failure Patients: Is There Room for Improvement?. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 2542-2550	15.1	23
267	Glucagon-Like Peptide 1 Receptor Activation Augments Cardiac Output and Improves Cardiac Efficiency in Obese Swine After Myocardial Infarction. 2017 , 66, 2230-2240		19
266	Physicians' guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. <i>European Journal of Heart Failure</i> , 2017 , 19, 1414-1423	12.3	126
265	Heart Rate and Rhythm and the Benefit of β -Blockers in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 2885-2896	15.1	132
264	Effects of carvedilol on structural and functional outcomes and plasma biomarkers in the mouse transverse aortic constriction heart failure model. 2017 , 5, 2050312117700057		3
263	Left ventricular ejection fraction as therapeutic target: is it the ideal marker?. <i>Heart Failure Reviews</i> , 2017 , 22, 641-655	5	13
262	Heart Failure with Myocardial Recovery - The Patient Whose Heart Failure Has Improved: What Next?. 2017 , 60, 226-236		16
261	Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study. 2017 , 38, 1883-1890		183

260	The evolution of heart failure with reduced ejection fraction pharmacotherapy: What do we have and where are we going?. 2017 , 178, 67-82		2
259	Feasibility and Association of Neurohumoral Blocker Up-titration After Cardiac Resynchronization Therapy. <i>Journal of Cardiac Failure</i> , 2017 , 23, 597-605	3-3	21
258	The Real Role of β Blockers in Daily Cardiovascular Therapy. 2017 , 17, 361-373		49
257	The association of volumetric response and long-term survival after cardiac resynchronization therapy. 2017 , 18, 1109-1117		16
256	Heart-type fatty acid-binding protein in cardiovascular disease: A systemic review. 2017 , 474, 44-53		25
255	2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. 2017 , 33, 1342-1433		330
254	Beta blocker dose and markers of sympathetic activation in heart failure patients: interrelationships and prognostic significance. <i>ESC Heart Failure</i> , 2017 , 4, 499-506	3-7	33
253	Real-world dosing of evidence-based medications for heart failure: embracing guideline recommendations and clinical judgement. <i>European Journal of Heart Failure</i> , 2017 , 19, 1424-1426	12-3	7
252	Myocardial Recovery After LVAD Implantation: A Vision or Simply an Illusion?. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 355-357	15-1	9
251	Declining Risk of Sudden Death in Heart Failure. 2017 , 377, 41-51		232
250	Adverse Remodeling and Reverse Remodeling After Myocardial Infarction. 2017 , 19, 71		82
249	Neurohormonal activation in heart failure with reduced ejection fraction. 2017 , 14, 30-38		185
248	Older adults with heart failure treated with carvedilol, bisoprolol, or metoprolol tartrate: risk of mortality. 2017 , 26, 81-90		3
247	Pediatric and adult dilated cardiomyopathy represent distinct pathological entities. 2017 , 2,		34
246	Effectiveness of implementation interventions in improving physician adherence to guideline recommendations in heart failure: a systematic review. 2018 , 8, e017765		36
245	Importance of baseline heart rate as a predictor of cardiac functional recovery in newly diagnosed heart failure with reduced ejection fraction. 2018 , 41, 752-757		2
244	The Future of Biomarker-Guided Therapy for Heart Failure After the Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) Study. 2018 , 15, 37-43		16
243	Defining the molecular signatures of human right heart failure. 2018 , 196, 118-126		13

242	Impaired Recovery of Left Ventricular Function in Patients With Cardiomyopathy and Left Bundle Branch Block. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 306-317	15.1	44
241	2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 201-230	15.1	173
240	What is the clinical significance of ventricular mural antagonism?. 2018 , 53, 714-723		5
239	Developing Drugs for Heart Failure With Reduced Ejection Fraction: What Have We Learned From Clinical Trials?. 2018 , 103, 802-814		3
238	Echocardiographic Insights into the Hemodynamics of Systolic Heart Failure: Can This Guide Titration of Medical Therapy?. 2018 , 31, 660-663		1
237	Inferential characterization of the dose-response relationships of neurohormonal antagonists in chronic heart failure: A novel approach based on large-scale trials with active comparators. 2018 , 261, 130-133		4
236	Innovation in pediatric clinical trials: The need to rethink the end-point. 2018 , 37, 431-432		1
235	Evidence-Based Therapy and Its Association With Workforce Detachment After First Hospitalization for Heart Failure. 2018 , 6, 41-48		1
234	A risk score to predict the absence of left ventricular reverse remodeling: Implications for the timing of ICD implantation in primary prevention. 2018 , 71, 505-512		3
233	Impact of systolic blood pressure on the safety and tolerability of initiating and up-titrating sacubitril/valsartan in patients with heart failure and reduced ejection fraction: insights from the TITRATION study. <i>European Journal of Heart Failure</i> , 2018 , 20, 491-500	12.3	37
232	Endothelial Phenotype Evoked by Low Dose Carvedilol in Pulmonary Hypertension. 2018 , 5, 180		2
231	Dose-independent influence of metoprolol on cardiac and motor functions, QoL, and mental status in Chinese patients with CHF. <i>Therapeutics and Clinical Risk Management</i> , 2019 , 15, 23-31	2.9	1
230	Introduction. 2018 , 1263-1264		
229	Long-term use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. 2018 , 13, e0199347		17
228	Beta blockers and chronic heart failure patients: prognostic impact of a dose targeted beta blocker therapy vs. heart rate targeted strategy. 2018 , 107, 1040-1049		9
227	Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction. 2018 , 6, CD012721		37
226	Mechanical Unloading in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 569-580	15.1	76
225	Combination drug therapy in heart failure: greater than the sum of its parts. <i>European Journal of Heart Failure</i> , 2018 , 20, 1323-1325	12.3	2

224	Beta-Adrenergic Receptor Blockade. 2018 , 539-542		
223	Role of High-Dose Beta-Blockers in Patients with Heart Failure with Preserved Ejection Fraction and Elevated Heart Rate. 2018 , 131, 1473-1481		17
222	Dose-dependent efficacy of β blocker in patients with chronic heart failure and atrial fibrillation. 2018 , 273, 141-146		10
221	Cardiac Ejection Fraction: New Insights About its Dynamic Nature. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 602-604	15.1	0
220	National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Guidelines for the Prevention, Detection, and Management of Heart Failure in Australia 2018. 2018 , 27, 1123-1208		141
219	Left bundle branch block-induced left ventricular remodeling and its potential for reverse remodeling. 2018 , 52, 343-352		11
218	Inhibition of hyperpolarization-activated cyclic nucleotide-gated channels by β blocker carvedilol. 2018 , 175, 3963-3975		9
217	Regular Treatment Strategy with a Large Amount of Carvedilol for Heart Failure Improves Biventricular Systolic Failure in a Patient with Repaired Tetralogy of Fallot. 2018 , 59, 1169-1173		2
216	Effect on Mortality of Higher Versus Lower β Blocker (Metoprolol Succinate or Carvedilol) Dose in Patients With Heart Failure. 2018 , 122, 994-998		5
215	Medical Therapy for Systemic Right Ventricles: A Systematic Review (Part 1) for the 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 1564-1578	15.1	12
214	Heart rate control using beta-blockers for heart failure with atrial fibrillation: more than enough is too much. 2019 , 42, 1826-1827		3
213	Phase 3 DREAM-HF Trial of Mesenchymal Precursor Cells in Chronic Heart Failure. 2019 , 125, 265-281		29
212	Physiologic expansion of human heart-derived cells enhances therapeutic repair of injured myocardium. 2019 , 10, 316		5
211	Reply: Titration of Guideline-Directed Medical Therapy Improves Patient-Centered Outcomes in Heart Failure With Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 1426-1427	15.1	2
210	β Adrenergic Blocker, Carvedilol, Abolishes Ameliorating Actions of Adipose-Derived Stem Cell Sheets on Cardiac Dysfunction and Remodeling After Myocardial Infarction. <i>Circulation Journal</i> , 2019 , 83, 2282-2291	2.9	4
209	Congestive Heart Failure in Children. 2019 , 40, 60-70		7
208	Comparison of 18-Month Outcomes of Ambulatory Patients With Reduced (\leq 40%) Left Ventricular Ejection Fraction Treated in a Community-Based, Dedicated Heart Failure Clinic Versus Treated Elsewhere. 2019 , 123, 1101-1108		
207	Medical therapy doses at hospital discharge in patients with existing and de novo heart failure. <i>ESC Heart Failure</i> , 2019 , 6, 774-783	3.7	11

206	Targeted Mono-Therapy for Newly Diagnosed Dilated Cardiomyopathy. <i>Journal of Cardiac Failure</i> , 2019 , 25, 686-689	3.3	0
205	Diagnostic tests, drug prescriptions, and follow-up patterns after incident heart failure: A cohort study of 93,000 UK patients. 2019 , 16, e1002805		16
204	Higher versus lower doses of ACE inhibitors, angiotensin-2 receptor blockers and beta-blockers in heart failure with reduced ejection fraction: Systematic review and meta-analysis. 2019 , 14, e0212907		18
203	Update on heart failure management and future directions. 2019 , 34, 11-43		48
202	Physicians' guideline adherence is associated with long-term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. <i>European Journal of Heart Failure</i> , 2019 , 21, 921-929	12.3	53
201	Pharmacotherapy in Heart Failure (II): Beta Adrenergic Blocking Drugs, Ivabradine, Hydralazine and Nitrates. 2019 , 121-127		
200	Target Doses of Heart Failure Medical Therapy and Blood Pressure: Insights From the CHAMP-HF Registry. 2019 , 7, 350-358		35
199	Left Ventricular Size and Ejection Fraction: Are They Still Relevant?. 2019 , 15, 147-158		4
198	Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS-HF trial. <i>European Journal of Heart Failure</i> , 2019 , 21, 345-351	12.3	28
197	Beta-Blocker Dose Stratifies Mortality Risk in a Racially Diverse Heart Failure Population. <i>Journal of Cardiovascular Pharmacology</i> , 2020 , 75, 250-258	3.1	0
196	[Austrian Consensus on High Blood Pressure 2019]. 2019 , 131, 489-590		3
195	Association between beta-adrenoceptor antagonist-induced sympathicolysis and severity of coronary artery disease as assessed by coronary computed tomography angiography (CCTA). 2019 , 35, 927-936		1
194	Hypertensive heart disease: Benefit of carvedilol in hemodynamic, left ventricular remodeling, and survival. 2019 , 7, 2050312118823582		3
193	Medication dosing for heart failure with reduced ejection fraction - opportunities and challenges. <i>European Journal of Heart Failure</i> , 2019 , 21, 286-296	12.3	32
192	Evidence-Based Management of the Patient with Congestive Heart Failure. <i>Contemporary Cardiology</i> , 2019 , 449-465	0.1	
191	Doses of renin-angiotensin system inhibitors but not beta-blockers predict outcome after ST-elevation myocardial infarction. 2019 , 74, 334-341		2
190	[Antagonistic function of the heart muscle : Part II: Clinical implications]. 2020 , 45, 178-185		
189	Contemporary Medical Therapy for Heart Failure Patients with Reduced Ejection Fraction. 2020 , 520-548		

188	Adrenergic Receptor Signaling in Heart Failure. 2020 , 91-102.e6		
187	Sympathetic overactivation predicts body weight loss in patients with heart failure. 2020 , 223, 102625	0	
186	Contemporary approach to treating heart failure. 2020 , 30, 507-518		3
185	Standardized definitions for evaluation of heart failure therapies: scientific expert panel from the Heart Failure Collaboratory and Academic Research Consortium. <i>European Journal of Heart Failure</i> , 2020 , 22, 2175-2186	12.3	8
184	Genetic, clinical, molecular, and pathogenic aspects of the South Asian-specific polymorphic MYBPC3 variant. 2020 , 12, 1065-1084		5
183	Standardized Definitions for Evaluation of Heart Failure Therapies: Scientific Expert Panel From the Heart Failure Collaboratory and Academic Research Consortium. 2020 , 8, 961-972		4
182	Beta-blockers in hypertension: overview and meta-analysis of randomized outcome trials. 2020 , 38, 1669-1681	17	
181	Heart Failure With Reduced Ejection Fraction: A Review. 2020 , 324, 488-504		139
180	2020 ACC/AHA Clinical Performance and Quality Measures for Adults With Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. 2020 , 13, e000099		18
179	Neurohormonal Blockade During Left Ventricular Assist Device Support. 2020 , 66, 881-885		2
178	2020 ACC/AHA Clinical Performance and Quality Measures for Adults With Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 2527-2564	15.1	13
177	Guideline-directed medical therapy for heart failure does not exist: a non-judgmental framework for describing the level of adherence to evidence-based drug treatments for patients with a reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2020 , 22, 1759-1767	12.3	21
176	Impact of sex-specific target dose in chronic heart failure patients with reduced ejection fraction. 2020 , 2047487320923185		5
175	Spirolactone dose in heart failure with preserved ejection fraction: findings from TOPCAT. <i>European Journal of Heart Failure</i> , 2020 , 22, 1615-1624	12.3	9
174	Phosphorylation of cardiac myosin-binding protein-C contributes to calcium homeostasis. 2020 , 295, 11275-11291		4
173	Left Ventricular Volume Reduction and Reshaping as a Treatment Option for Heart Failure. 2020 , 4, 264-283		4
172	Effects of combined renin-angiotensin-aldosterone system inhibitor and beta-blocker treatment on outcomes in heart failure with reduced ejection fraction: insights from BIostat-CHF and ASIAN-HF registries. <i>European Journal of Heart Failure</i> , 2020 , 22, 1472-1482	12.3	14
171	In-hospital and long-term mortality for acute heart failure: analysis at the time of admission to the emergency department. <i>ESC Heart Failure</i> , 2020 , 7, 2650-2661	3.7	8

170	Long-term outcome of carvedilol therapy in Japanese patients with nonischemic heart failure. 2020 , 35, 957-966		2
169	Heart failure in single right ventricle congenital heart disease: physiological and molecular considerations. 2020 , 318, H947-H965		17
168	Management of low blood pressure in ambulatory heart failure with reduced ejection fraction patients. <i>European Journal of Heart Failure</i> , 2020 , 22, 1357-1365	12.3	18
167	Target Doses of Secondary Prevention Medications Are Not Being Achieved in Patients With Reduced Left Ventricular Ejection Fraction After Acute Coronary Syndrome (ANZACS-QI 34). 2020 , 29, 1386-1396		1
166	Body surface area and medication dosing in patients with heart failure with reduced ejection fraction. 2021 , 31, 111-116		1
165	Beyond genomics-technological advances improving the molecular characterization and precision treatment of heart failure. <i>Heart Failure Reviews</i> , 2021 , 26, 405-415	5	4
164	Reverse Cardiac Remodeling and ARNI Therapy. 2021 , 18, 71-83		6
163	2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 772-810	15.1	216
162	Implication of Ivabradine in Up-titrating Beta-blocker in a Patient with Advanced Heart Failure. 2021 , 60, 897-900		2
161	Beta-blocker and ACE-inhibitor dosing as a function of body surface area: From the HF-ACTION trial. <i>American Heart Journal</i> , 2021 , 233, 1-4	4.9	0
160	Pharmacotherapy for heart failure with reduced ejection fraction and health-related quality of life: a systematic review and meta-analysis. <i>European Journal of Heart Failure</i> , 2021 , 23, 578-589	12.3	5
159	Evaluation of Sacubitril/Valsartan Initiation in Outpatient Heart Failure Patients. <i>Journal of Cardiovascular Pharmacology</i> , 2021 , 77, 343-348	3.1	
158	Four pillars of heart failure: contemporary pharmacological therapy for heart failure with reduced ejection fraction. 2021 , 8,		7
157	Virtual optimization of guideline-directed medical therapy in hospitalized patients with heart failure with reduced ejection fraction: the IMPLEMENT-HF pilot study. <i>European Journal of Heart Failure</i> , 2021 , 23, 1191-1201	12.3	11
156	CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction. 2021 , 37, 531-546		48
155	Association Between Physical Status and the Effects of Combination Therapy With Renin-Angiotensin System Inhibitors and BBlockers in Patients With Acute Heart Failure. 2021 , 3, 217-226		0
154	The Optimal Timing of Primary Prevention Implantable Cardioverter-Defibrillator Referral in the Rapidly Changing Medical Landscape. 2021 , 37, 644-654		2
153	Rapid evidence-based sequencing of foundational drugs for heart failure and a reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2021 , 23, 882-894	12.3	26

152	Perceived risk profile and treatment optimization in heart failure: an analysis from BIOlogy Study to Tailored Treatment in chronic heart failure. 2021 , 44, 780-788		1
151	Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction. 2021 , 5, CD012721		3
150	Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden). <i>European Journal of Heart Failure</i> , 2021 , 23, 1499-1511 ^{12,3} ¹³		
149	Suboptimal Dosing of β Blockers in Chronic Heart Failure: A Missed Opportunity?. 2021 ,		
148	Role of Guideline Directed Medical Therapy Doses and Optimization in Patients Hospitalized With Decompensated Systolic Heart Failure. 2021 , 151, 64-69		1
147	Current concept in the diagnosis, treatment and rehabilitation of patients with congestive heart failure. 2021 , 13, 183-203		1
146	Simultaneous or rapid sequence initiation of medical therapies for heart failure: seeking to avoid the case of 'too little, too late'. <i>European Journal of Heart Failure</i> , 2021 , 23, 1514-1517	12,3	2
145	Unique Positive Cooperativity Between the β -Arrestin-Biased β -Blocker Carvedilol and a Small Molecule Positive Allosteric Modulator of the α_2 -Adrenergic Receptor. 2021 , 100, 513-525		3
144	Importance of Optimized Guideline-Based Therapy for Preventing Rehospitalization of Chronic Heart Failure Patients - From the KUNIUMI Acute Cohort. 2021 , 3, 511-519		
143	Effect of disease-modifying agents and their association with mortality in multi-morbid patients with heart failure with reduced ejection fraction. <i>ESC Heart Failure</i> , 2020 , 7, 3859	3-7	4
142	Therapeutics in Congestive Heart Failure: From Hemodynamics to Neurohormones. 2003 , 17-34		2
141	The Autonomic Nervous System. 2010 , 261-304		7
140	Development and Implementation of Practice Guidelines in Heart Failure. 2011 , 594-609		1
139	Sympatholytic therapy in primary hypertension: a user friendly role for the future.		1
138	Recipient selection and management before cardiac transplantation. 1997 , 314, 139-52		16
137	Cellular events linked to cardiac remodeling in heart failure: targets for pharmacologic intervention. 2000 , 14, 1-23; quiz 119-20		13
136	Ejection fraction improvement by beta-blocker treatment in patients with heart failure: an analysis of studies published in the literature. <i>Journal of Cardiovascular Pharmacology</i> , 1998 , 32 Suppl 1, S31-5	3-1	3 ¹
135	Beta-blockers for chronic heart failure: from prejudice to enlightenment. <i>Journal of Cardiovascular Pharmacology</i> , 1998 , 32 Suppl 1, S52-60	3-1	4

134	Cardiovascular effects of nepicastat (RS-25560-197), a novel dopamine beta-hydroxylase inhibitor. <i>Journal of Cardiovascular Pharmacology</i> , 1998 , 31, 963-70	3.1	7
133	Maximal and Submaximal Exercise Testing in Heart Failure. <i>Journal of Cardiovascular Pharmacology</i> , 1998 , 32, S36-S45	3.1	4
132	Comparative effects of carvedilol and metoprolol on cardiac ischemia-reperfusion injury. <i>Journal of Cardiovascular Pharmacology</i> , 1998 , 32, 443-51	3.1	18
131	Heart Failure due to Ischaemic Heart Disease: Epidemiology, Pathophysiology and Progression. <i>Journal of Cardiovascular Pharmacology</i> , 1999 , 33, S17-S29	3.1	14
130	Heart failure due to ischaemic heart disease: epidemiology, pathophysiology and progression. <i>Journal of Cardiovascular Pharmacology</i> , 1999 , 33 Suppl 3, S17-29	3.1	22
129	Carvedilol enhances atrial and brain natriuretic peptide mRNA expression and release in rat heart. <i>Journal of Cardiovascular Pharmacology</i> , 2000 , 36 Suppl 2, S19-23	3.1	28
128	Implementation strategies to manage heart failure outcomes. 2000 , 11, 396-411		12
127	Hypoxia sensing through α -adrenergic receptors. 2016 , 1, e90240		22
126	A personalized BEST: characterization of latent clinical classes of nonischemic heart failure that predict outcomes and response to bucindolol. 2012 , 7, e48184		17
125	Isoproterenol induces vascular oxidative stress and endothelial dysfunction via a G β -coupled β -adrenoceptor signaling pathway. 2014 , 9, e91877		38
124	Recent Patient Characteristics and Medications at Admission and Discharge in Hospitalized Patients With Heart Failure. 2016 , 8, 97-104		3
123	The Change in Body Weight During Hospitalization Predicts Mortality in Patients With Acute Decompensated Heart Failure. 2017 , 9, 200-206		2
122	Decline of plasma brain natriuretic peptide level after carvedilol therapy to treat dilated cardiomyopathy presenting with mechanical alternans. 2007 , 48, 117-21		1
121	Expert Comment: Is Medication Titration in Heart Failure too Complex?. <i>Cardiac Failure Review</i> , 2017 , 3, 25-32	4.2	16
120	A Risk Score to Predict the Absence of Left Ventricular Reverse Remodelling: Implications for the Timing of ICD Implantation in Primary Prevention. 2017 , 12, 99		1
119	A practical guide for the treatment of symptomatic heart failure with reduced ejection fraction (HFrEF). 2015 , 11, 23-32		15
118	Using Carvedilol to Treat Heart Failure. 2002 , 22, 36-58		3
117	Switching to Once-Daily Evidence-Based β -Blockers in Patients With Systolic Heart Failure or Left Ventricular Dysfunction After Myocardial Infarction. 2007 , 27, 62-72		2

116	Moisture Sorption-desorption Characteristics and the Corresponding Thermodynamic Properties of Carvedilol Phosphate. 2017 , 9, 16-21	1
115	Preventive role of carvedilol in adriamycin-induced cardiomyopathy. 2016 , 144, 725-729	25
114	Comparative analysis of the quality of life of heart failure patients in South Western Nigeria. 2013 , 03, 146-153	6
113	Discharge heart rate and future events among Japanese patients with acute heart failure receiving beta-blocker therapy. 2013 , 03, 159-167	1
112	Comparison of chronic systolic heart failure guideline adherence for two ambulatory clinics. 2010 , 8, 56-61	1
111	Effects of Silibinin on the Pharmacokinetics of Carvedilol after Oral Administration in Rats. 2011 , 41, 153-159	3
110	Optimized treatment and heart rate reduction in chronic heart failure. 2013 , 101, 442-8	2
109	Beta-blockers are associated with reverse remodeling in patients with dilated cardiomyopathy and mid-range ejection fraction. 2021 , 11, 100053	
108	Akute kardiale Dyspnoe und Lungenödem. 2000 , 527-538	
107	Pathophysiologie der chronischen Herzinsuffizienz. 2000 , 545-595	
106	Klinik und Symptomatologie der chronischen Herzinsuffizienz. 2000 , 597-610	
105	βBlocker treatment of chronic heart failure with special regard to Carvedilol. 2000 , 257-275	
104	Oxidative Stress and Use of Antioxidants in Patients with Congestive Heart Failure. 2000 , 211-224	
103	Definition und Epidemiologie der chronischen Herzinsuffizienz. 2000 , 539-543	
102	????????(????1999????). <i>Journal of JCS Cardiologists</i> , 2000 , 8, 107-112	0.1
101	Adrenergic Blockade in Heart Failure [Official Guidelines and Practical Recommendations on Optimal Use. 2001 , 117-130	
100	Behandlung der Herzinsuffizienz mit βBlockern [Mechanismen und klinische Ergebnisse. 2001 , 24-38	
99	The role of beta-blockers in the management of patients with heart failure. 2001 , 20, 24-9	

- 98 Are All β Blockers the Same for Heart Failure? Insights from Clinical Trials and Future Research Directions. **2001**, 80-95
- 97 Anti-Adrenergic Therapy in Hypertensive Patients with Concomitant Disease. **2001**, 16-28
- 96 The Role of Multiple Adrenergic Blockade in Coronary Artery Disease and Myocardial Infarction. **2001**, 39-53
- 95 Carvedilol: a countermeasure to heart failure. **2001**, 20, 11-6
- 94 β Blockers. **2002**, 211-221
- 93 Current research on carvedilol in heart failure. **2002**, 22, 14-16
- 92 Effects of the Beta-Adrenoceptor Blocker Carvedilol in Children with Myocardial Failure. **2003**, 123-133
- 91 Herz, Gefäß, Lunge. **2004**, 81-196
- 90 β Blockers. **2005**, 213-228
- 89 Congestive Heart Failure. **2006**, 83-95
- 88 Exercise Testing in Patients with Heart Failure and Left Ventricular Dysfunction. **2006**, 329-350
- 87 Beta-Blockers in Heart Failure. **2006**, 113-136
- 86 Congestive Heart Failure: Epidemiology, Pathophysiology, and Current Therapies. **2006**, 525-544
- 85 Pharmacologic Management of Heart Failure in the Ambulatory Setting. **2007**, 331-362
- 84 The Medical Management of Heart Failure. **2007**, 1397-1416
- 83 Magnetic Resonance Imaging of the Myocardium. **2007**, 871-896
- 82 β Adrenoceptor-Linked Signal Transduction Mechanisms in Congestive Heart Failure. **2008**, 27-49
- 81 Acute Heart Failure and Myocarditis. **2008**, 183-199

- 80 Management of Chronic Heart Failure Therapy in the Setting of Acute Heart Failure. **2008**, 533-544
- 79 Traitement de l'insuffisance cardiaque. **2008**, 101-125
- 78 Cardiac Failure. **2009**, 557-572
- 77 Medical Therapy for Heart Failure. **2010**, 29-68
- 76 Evidence-Based Management of the Patient with Congestive Heart Failure. **2011**, 497-518
- 75 Myocarditis and Acute Myopathies. **2011**, 613-624
- 74 Cardiovascular Disease. **2012**, 478-549
- 73 Congestive Heart Failure. **2014**, 2045-2062
- 72 β -Blocker Treatment of Chronic Heart Failure. **1998**, 177-205
- 71 The Role of β -Blockers in the Management of Heart Failure: Results of Controlled Trials. **1998**, 245-253
- 70 Treatment of Dilated Cardiomyopathies with β -Adrenergic Blocking Agents. **1998**, 236-244
- 69 Ejection Fraction Improvement by β -Blocker Treatment in Patients with Heart Failure. *Journal of Cardiovascular Pharmacology*, **1998**, 32, S31-S35 3.1 34
- 68 β -Adrenergic Antagonists in the Management of Acute Myocardial Infarction. **1998**, 41-56
- 67 Heart Failure: Treatment with β -Adrenoceptor Antagonists. **1998**, 207-232
- 66 Maximal and submaximal exercise testing in heart failure. *Journal of Cardiovascular Pharmacology*, **1998**, 32 Suppl 1, S36-45 3.1 8
- 65 Medical Treatment of Heart Failure: Problems in Dilated Cardiomyopathy. **1998**, 229-235
- 64 β -Blockers for Chronic Heart Failure. *Journal of Cardiovascular Pharmacology*, **1998**, 32, S52-S60 3.1 2
- 63 ?????????(????1997????). *Journal of JCS Cardiologists*, **1998**, 6, 81-92 0.1

62	The role of neurohormonal antagonists in hibernating myocardium. <i>Journal of Cardiovascular Pharmacology</i> , 1999 , 33 Suppl 3, S9-16	3.1	
61	Ischemic and nonischemic heart failure do not require different treatment strategies. <i>Journal of Cardiovascular Pharmacology</i> , 1999 , 33 Suppl 3, S1-7	3.1	1
60	Ischemic and Nonischemic Heart Failure do not Require Different Treatment Strategies. <i>Journal of Cardiovascular Pharmacology</i> , 1999 , 33, S1-S7	3.1	6
59	The Role of Neurohormonal Antagonists in Hibernating Myocardium. <i>Journal of Cardiovascular Pharmacology</i> , 1999 , 33, S9-S16	3.1	1
58	Neurohormonal Blockade in Heart Failure. 2015 , 77-111		
57	2014 Korean Guidelines for Appropriate Utilization of Cardiovascular Magnetic Resonance Imaging: A Joint Report of the Korean Society of Cardiology and the Korean Society of Radiology. <i>Journal of the Korean Society of Radiology</i> , 2015 , 72, 217	0.2	
56	Outpatient Medication Titration in Acute Heart Failure. <i>Contemporary Cardiology</i> , 2017 , 243-258	0.1	
55	Pharmacological Treatment of Chronic Heart Failure. <i>Journal of the Nihon University Medical Association</i> , 2020 , 79, 209-215	0	
54	Perspective on the role of four beta-blockers in heart failure. <i>Current Reviews in Clinical and Experimental Pharmacology</i> , 2021 ,		
53	Revisiting the clinical evidence of heart rate target in patients with heart failure treated with beta-blockers. <i>Anatolian Journal of Cardiology</i> , 2021 , 25, 762-773	0.8	
52	Advanced Heart Failure Management and Selection for Advanced Therapies. <i>Advances in Medical Technologies and Clinical Practice Book Series</i> , 216-235	0.3	
51	Cardiac Resynchronisation Therapy in Patients with NYHA Class III. 2006 , 511-517		
50	Beta blocker therapy and prevention of apoptosis. 2000 , 309-316		
49	Is forced titration of beta-blockers more effective than usual beta-blocker therapy in improving heart failure with reduced ejection fraction outcomes?. <i>Evidence-Based Practice</i> , 2020 , Publish Ahead of Print,	0	
48	Discontinuation of Cardiac Resynchronization Therapy for Heart Failure Due to Dilated Cardiomyopathy in a 61-Year-Old Female "-Super-Responder" with Return of a Reduced Left Ventricular Ejection Fraction to Normal. <i>American Journal of Case Reports</i> , 2020 , 21, e926704	1.3	1
47	Treating relentlessly progressive congestive heart failure: what next?. <i>Texas Heart Institute Journal</i> , 1998 , 25, 235-7	0.8	4
46	Effects of carvedilol on plasma levels of pro-inflammatory cytokines in patients with ischemic and nonischemic dilated cardiomyopathy. <i>Texas Heart Institute Journal</i> , 2007 , 34, 52-9	0.8	18
45	Carvedilol. <i>Canadian Family Physician</i> , 1999 , 45, 1199-202, 1205-9	0.9	

44	Beta-adrenergic receptor antagonists and chronic heart failure in children. <i>Therapeutics and Clinical Risk Management</i> , 2007 , 3, 847-54	2.9	3
43	Beta blockers in heart failure haemodynamics, clinical effects and modes of action. <i>Netherlands Heart Journal</i> , 2001 , 9, 334-342	2.2	1
42	Dilated cardiomyopathy in childhood. <i>Images in Paediatric Cardiology</i> , 2000 , 2, 3-10		7
41	Higher medication doses in heart failure?. <i>Canadian Family Physician</i> , 2017 , 63, e20	0.9	
40	Beta-blocker treatment in heart failure patients with atrial fibrillation: challenges and perspectives. <i>Journal of Geriatric Cardiology</i> , 2021 , 18, 362-375	1.7	
39	Comparative Effectiveness of Dosing of Medical Therapy for Heart Failure: From the CHAMP-HF Registry. <i>Journal of Cardiac Failure</i> , 2021 ,	3.3	0
38	Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. <i>Lancet Diabetes and Endocrinology</i> , 2021 ,	18.1	3
37	The Gap to Fill: Rationale for Rapid Initiation and Optimal Titration of Comprehensive Disease-modifying Medical Therapy for Heart Failure with Reduced Ejection Fraction.. <i>Cardiac Failure Review</i> , 2021 , 7, e18	4.2	3
36	Dose-limiting, adverse event-associated bradycardia with Eblocker treatment of atrial fibrillation in the GENETIC-AF trial.. <i>Heart Rhythm O2</i> , 2022 , 3, 40-49	1.5	
35	Heart Failure. 2022 , 103-155		
34	A dose-response relationship of renin-angiotensin system blockers and beta-blockers in patients with acute heart failure syndrome: a nationwide prospective cohort study.. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022 ,	6.4	3
33	Clinical Effect of Pulmonary Artery Diameter/Ascending Aorta Diameter Ratio on Left Ventricular Reverse Remodeling in Patients With Dilated Cardiomyopathy.. <i>Circulation Journal</i> , 2022 ,	2.9	0
32	Drug therapy for HFrEF: What is the "right" dose?. <i>European Journal of Heart Failure</i> , 2022 ,	12.3	2
31	Medical Management of Patients With Heart Failure and Reduced Ejection Fraction.. <i>Korean Circulation Journal</i> , 2022 , 52, 173-197	2.2	2
30	Association Between Dosing And Combination Use Of Medications And Outcomes In Heart Failure With Reduced Ejection Fraction: Data From The Swedish Heart Failure Registry.. <i>European Journal of Heart Failure</i> , 2022 ,	12.3	1
29	Optimal effectiveness of heart failure management - an umbrella review of meta-analyses examining the effectiveness of interventions to reduce (re)hospitalizations in heart failure.. <i>Heart Failure Reviews</i> , 2022 , 1	5	2
28	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.. <i>Circulation</i> , 2022 , 101161CIR0000000000001063	16.7	35
27	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.. <i>Journal of the American College of Cardiology</i> , 2022 ,	15.1	49

26	Heart failure treatment in patients with cardiac implantable electronic devices: Opportunity for improvement.. <i>Heart Rhythm O2</i> , 2021 , 2, 698-709	1.5	0
25	Left ventricular reverse remodelling and its predictors in non-ischaemic cardiomyopathy.. <i>ESC Heart Failure</i> , 2022 ,	3.7	0
24	Data_Sheet_1.docx. 2018 ,		
23	THE EVALUATION OF THE TREATMENT WITH THE EXERCISE TISSUE DOPPLER ECHOCARDIOGRAPHIC PARAMETERS WITH NEBIVOLOL TREATMENT IN PATIENTS WITH HEART FAILURE. <i>Cumhuriyet Medical Journal</i> ,	0	
22	Medical Therapies for Heart Failure in Hypoplastic Left Heart Syndrome. <i>Journal of Cardiovascular Development and Disease</i> , 2022 , 9, 152	4.2	
21	Daily Ambulatory Remote Monitoring System for Drug Escalation in Chronic Heart Failure with Reduced Ejection Fraction: Pilot Phase of DAVID-HF Study. <i>European Heart Journal Digital Health</i> ,	2.3	0
20	Titration of medical therapy and clinical outcomes among patients with heart failure with reduced ejection fraction: findings from the HF-ACTION trial. <i>American Heart Journal</i> , 2022 , 251, 115-115	4.9	0
19	Frequency, predictors and cardiovascular outcomes associated with transthoracic echocardiographic findings during acute ischaemic stroke hospitalisation. <i>Stroke and Vascular Neurology</i> , svn-2021-001170	9.1	
18	Impact of R-Carvedilol on α -Adrenergic Receptor-Mediated Spontaneous Calcium Release in Human Atrial Myocytes. <i>Biomedicines</i> , 2022 , 10, 1759	4.8	1
17	Management of Atrial Fibrillation Across the Spectrum of Heart Failure With Preserved and Reduced Ejection Fraction. 2022 , 146, 339-357		1
16	Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction. 2022 , 328, 259		2
15	Guideline-Directed Medical Therapy Before and After Primary Prevention Implantable Cardioverter Defibrillator Implantation in New Zealand (ANZACS-QI 66). 2022 ,		
14	Reviewing the Modern Therapeutical Options and the Outcomes of Sacubitril/Valsartan in Heart Failure. 2022 , 23, 11336		1
13	Cardiopulmonary function during exercise in heart failure with reduced ejection fraction following baroreflex activation therapy. 2022 , 16, 175394472211312		0
12	Clinical outcomes in heart failure with reduced left ventricular ejection fraction and good functional capacity: The illusion of stability. 2022 ,		0
11	Identification of predictive factors interacting with heart rate reduction for potential beneficial clinical outcomes in chronic heart failure: A systematic literature review and meta-analysis. 2022 , 43, 101141		0
10	Pathophysiology and Management of Heart Failure in the Elderly.		0
9	R-carvedilol, a potential new therapy for Alzheimer's disease. 13,		0

- 8 Regression of cardiac hypertrophy in health and disease: mechanisms and therapeutic potential. ○
- 7 Management of Heart Failure with Reduced Ejection Fraction. **2023**, 101596 ○
- 6 Misconceptions and Facts about Heart Failure with Reduced Ejection Fraction. **2023**, ○
- 5 II. Details: Therapeutic Agents for Chronic Heart Failure; 4. β -blocker and Ivabradine. **2022**, 111, 241-247 ○
- 4 β -blocker Exposure in Pregnancy and the Risk of Neonatal Hypoglycemia and Small for Gestational Age. **2023**, 87, 569-577 ○
- 3 Heart failure with reduced ejection fraction and atrial fibrillation: a Sub-Saharan African perspective. ○
- 2 Treatment Strategies of Improving Quality of Care in Patients With Heart Failure. 53, ○
- 1 Impact of a Nurse-Led Multidisciplinary Heart Failure Clinic in a Low Resource Setting: Experience in a Latin American Public Healthcare system. **2023**, ○